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Abstract 
 
 
Oil in water nanoemulsions (O/W NEs) represent an ideal vehicle for drug 
delivery thanks to their ability to dissolve large quantities of hydrophobic 
drugs and protect their cargo from hydrolysis and enzymatic degradation. 
The stabilization of O/W NEs by means of a polymer coating, obtained 
through the layer by layer methodology (LbL), and the polyethylene glycol 
(PEG) conjugation are extremely important respectively to prolong the shelf 
life of the product and the period of blood stream circulation. In this 
perspective the first part of my thesis project concerns the complete 
physicochemical characterization of oil in water nanoemulsions coated with 
a polyelectrolyte (namely secondary NE) in order to identify polymer 
concentration domains that are thermodynamically stable and to define the 
degree of stability through thermodynamic functions depending upon 
relevant parameters affecting the stability itself, such as type of polymer 
coating, droplet distance, etc. This study was very important for the build-up 
of optimal oil in water secondary nanoemulsions (SNE).  
The second part of the Ph.D. work was focused on the improvement of O/W 
SNEs functioning as drug delivery systems in the human body based on the 
development of a decoration strategy by means of two macromolecules: the 
PEG as a molecule that increases availability of the nanocarrier in the blood 
stream, and a peptide as a molecule able to target the nanocarrier to a 
specific district. Herein, a cell penetrating peptide (CPP) that crosses 
cellular membranes was chosen as a model, anyway simply removing the 
peptide or substituting it with a ligand of a specific cell-receptor it is 
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possible to obtain a nanocarrier that in view of its small size (below 200 nm) 
can promote passive targeting to tumors through the extravasation 
mechanism or a nanocarrier prone to active targeting, respectively. The last 
part of the Ph.D. study was focused on the development of a method able to 
identify receptors overexpression on specific cell lines. The methodology, 
based on Isothermal Titration Calorimetry (ITC) coupled with confluent cell 
layers cultured around biocompatible templating microparticles can be very 
helpful to identify targets, to address drug design and selectively deliver 
therapeutics that can cross biological barriers. 
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CHAPTER I   Introduction 
 
 
1.1. Nanotechnologies and Nanomedicine 
 
Nanotechnology is increasingly considered to be the technology of the 
future (1), it consists in the confinement of functional systems at the 
molecular scale. ‘‘There’s plenty of room at the bottom’’ is the title of the 
lecture that Richard Feynman gave in 1959 at the annual meeting of the 
American Physical Society introducing the concept of nanotechnology as an 
important field for future scientific researches (2). During his lecture he 
asked his audience: 
“I don’t know how to do this on a small scale in a practical way, but I do 
know that computing machines are very large; they fill rooms. Why can’t 
we make them very small, make them of little wires, little elements, and by 
little, I mean little?” 
This lecture is still seen as a seminal event in the short history of the nano-
field. Technological advances had been made in the nano-world since 
Feynman’s talk. In these years, nanotechnology research has been widely 
developed in the field of communications, engineering, chemistry, physics, 
robotics, biology, and medicine. In particular nanotechnology represents a 
powerful tool in the field of medicine, where it has been utilized for the 
development of novel drug delivery systems (DDS) through the entrapment 
of the pharmaceutical agent in nanoparticulate systems aimed to the 
treatments of a variety of diseases and disorders (3). Nanomedicine offers an 
avenue where nanoscale systems could easily enter cells and tissues to 
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interact with DNA and proteins. In other words, the nanoscale systems work 
as nanocarriers for the delivery of drugs. Since 1970 controlled DDSs have 
attracted huge interest and great progresses have been reached (4). In fact 
despite being only several decades old, research in nanomedicine has 
already led to the development of a wide range of products including 
diagnostics, and medical devices. Nowadays, there are more than 200 
nanomedicine products that have been either approved or are under clinical 
investigation (5,6). The use of a drug delivery system is useful to enhance 
the efficacy and safety of therapeutic agents, and overcome any drawbacks 
of the agents, such as toxicity, low water solubility and poor bioavailability. 
Moreover, one of the most important advantages of nano-DDS is drug 
targeting, which may utilize physiology of a normal tissue or 
pathophysiological properties unique of an ill tissue to address the nano-
DDS to a specific target (7,8). 
 
 
 
1.2. Common Features of Targeting Drug Delivery Systems 
 
In the design of a DDS it is useful to do a distinction among different types 
of targeting.  
It is known that under certain circumstances (inflammation/hypoxia, first of 
all, which is typical for tumors, infarcts, and some other pathological sites in 
the body) the endothelial lining of the blood vessel wall becomes more 
permeable than in the normal state. As a result, in such areas, particles 
ranging from 10 to 500 nm in size, can leave the vascular bed and 
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accumulate inside the interstitial space. If these particles are loaded with a 
pharmaceutical agent, they can bring it into the area with the increased 
vascular permeability, and eventually release there the active drug. Such 
spontaneous accumulation or “passive” targeting, is currently known as 
enhanced permeability and retention (EPR) effect (9). In other words, high 
permeability of a damaged vasculature allows macromolecules and 
nanoparticles to enter the tumor interstitial space, while the compromised 
lymphatic filtration allows them to stay there. To follow this pathway, the 
ideal size of the nanocarrier is below 200 nm (10).  
Differently from EPR, the nanocarrier delivery to particular locations within 
the body by targeting specific cell types is called “active” targeting. In other 
words, it consists in the attachment of ligands to the outer surface of 
nanoparticles that become able to specifically bind to target receptors 
present in certain sites such as cell surface or extracellular matrix. For 
instance, nanocarriers loaded with anticancer drugs can be modified with 
antibodies that target tumor-specific antigens or with ligands that bind to 
upregulated receptors present on tumor cells. This interaction induces an 
uptake by a receptor mediated endocytosis pathway in which plasma-
membrane region containing the receptor-ligand complex undergoes 
endocytosis, becoming a transport vesicle (Fig. 1.1). 
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Figure 1.1 Schematic representations of passive (left) and active (right) 
drug–tumor targeting. In passive delivery, vesicular nanoparticles 
extravasate through leaky vasculature, accumulate, and release the 
encapsulated drugs; whereas in active targeting delivery, ligands attached 
vesicles extravasated through leaky vasculature specifically bind to cancer 
surface cell receptors followed by receptor-mediated endocytosis. Drugs 
could be released either extracellularly, or intracellularly through 
endocytosis (adapted to ref. 10 and 11). 
 
The other approach for the delivery of nanoparticles is the use of small 
naturally derived peptides called cell penetrating peptides (CPPs) or protein 
transduction domains (PTDs) that cross cellular membranes efficiently. 
Very generally, CPPs are up to 30 amino acid amphiphilic peptides, which 
can be internalized by cells by mechanisms that require no energy and are 
receptor mediated or not. Historically, the first observation was made in 
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1988, by Frankel and Pabo, who showed that the transcription 
transactivating (Tat) protein of HIV-1 could enter cells and translocate into 
the nucleus (13). Subsequently, the group of Lebleu identified the minimal 
peptide sequence of Tat required for cellular uptake 
(47YGRKKRRQRRR57) (14). Ever since many other CPPs have been 
designed; among these the nineteen residues peptide, named gH625, 
identified as a membrane-perturbing domain in the glycoprotein gH of 
Herpes simplex virus type I, has attracted much interest (15). gH625, 
contributing to the merging of the viral envelope and the cellular membrane 
is able to traverse the membrane bilayer and transport a cargo into the 
cytoplasm. Although the mechanism of CPPs uptake into the cell is still 
under debate, this class of peptide is able to trigger the movement of various 
cargos into cells, including small molecules, peptides, proteins, DNA/RNA, 
nanocarriers, and other supramolecular aggregates. CPPs thus constitute a 
new class of potential drug delivery vectors. 
Clearly, any type of targeting requires the drug delivery systems to be long-
circulating in order to provide a sufficient level of accumulation in the 
target. Decoration of DDSs with poly(ethylene glycol) (PEG) chains is a 
well-known strategy to inhibit their clearance and allows them to stay in the 
blood for extended periods of time. PEG is a coiled polymer of repeating 
ethylene ether units with dynamic conformation. The movement of PEG 
chains conjugated on nanoparticles reduces the interaction with opsonin 
proteins and the subsequent association with macrophages (16). In this way 
PEGylated nanoparticles generally have an increased circulation time in 
blood stream with respect to the non-PEGylated nanoparticles (Fig. 1.2). 
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Figure 1.2 Polyethylene glycol prevents uptake by the reticuloendothelial 
system (A). Nanoparticles (A1) are coated with opsonin proteins (A2) and 
associate with macrophages (A3) for transit to the liver (A4). Macrophages 
stationary in the liver, known as Kupffer cells, also participate in 
nanoparticle scavenging. (B) Nanoparticles coated with PEG (B1) prevents 
this opsonization (B2), resulting in decreased liver accumulation (B3) and 
increased availability of the NP in the blood steam (adapted to ref. 16). 
 
In this dissertation, we focused on the set up of PEGylated DDSs decorated 
with a CPPs as a model peptide, anyway simply removing the peptide or 
substituting it with a ligand of a specific cell-receptor it is possible to fit the 
nanocarrier respectively for passive or active targeting. 
Regarding the composition, nanocarriers can be made of biocompatible and 
biodegradable materials such as synthetic proteins, peptides, lipids, 
polysaccharides, biodegradable polymers and fibers (18). Herein, we 
meanly focused on lipid-based nanoparticles, in particular on 
nanoemulsions, since the most of newly developed drugs are hydrophobic in 
nature (19). 
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1.3. Nanoemulsions 
 
An emulsion is a biphasic system in which one phase is intimately dispersed 
in the other phase in the form of minute droplets generally ranging in 
diameter from 0.1 to 100 µm. The dispersed phase is also known as internal 
phase or discontinuous phase while the outer phase is called dispersion 
medium, external phase or continuous phase. The term ‘nanoemulsion’ 
refers to a mini-emulsion which is fine oil/water or water/oil dispersion 
stabilized by an interfacial film of surfactant molecule having droplet size in 
the range 20–500 nm. There are three types of nanoemulsions which can be 
formed: (a) oil in water nanoemulsion (O/W NE) in which oil is dispersed in 
the continuous aqueous phase, (b) water in oil nanoemulsion (W/O NE) in 
which water droplets are dispersed in the continuous oil phase, and (c) bi-
continuous nanoemulsions. O/W NE can be suitable as the basis of many 
kinds of foods (e.g., milk, cream, beverages, dressings, etc.) (20), as well as 
cosmetics (lotions, transparent milks, and crystal-clear gels) (21). Further, 
their ability to dissolve large quantities of hydrophobics and protect their 
cargo from hydrolysis and enzymatic degradation makes O/W NEs ideal 
vehicles for the purpose of drug delivery. Digestible oils such as soybean 
oil, sesame seed oil, cottonseed oil and safflower oil are often used to 
prepare O/W NEs where to dissolve the lipophilic drugs. An O/W NE is 
generally produced by homogenizing oil and water together in the presence 
of an emulsifier that rapidly adsorbs to the surface of oil droplets during 
homogenization improving the NE stability (22). A vigorous blending of 
only oil and water may yield a crude temporary emulsion, which upon 
standing, will separate in two distinct phases due to the coalescence of the 
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dispersed globules, whereas the presence of an emulsifier makes the 
nanoemulsion a stable system. An emulsion formed by small anionic 
droplets coated with a layer of emulsifier is called primary emulsion (Fig. 
1.3). 
 
 
Figure 1.3 Illustration of an oil in water nanoemulsion stabilized by an 
emulsifier molecule (primary nanoemulsion) (adapted to ref 23). 
 
However, even though stabilized by the use of emulsifiers, emulsions do not 
typically have a sufficiently long shelf life and they present destabilization 
mechanisms such as creaming, sedimentation, coalescence and Ostwald 
ripening (24). The combination of lipids and polyelectrolytes is often used 
as a facile method to optimize the physicochemical properties of 
nanoemulsions; an example is represented by SNEs. A secondary emulsion 
is formed by a primary emulsion coated with a layer of a polyelectrolyte that 
is produced by adding the polymer to the primary emulsion. The electrical 
charge on the droplets increases from negative to positive when the 
polyelectrolyte is added to the emulsion indicating that the polymer is 
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adsorbed to the droplet surface. It has been shown that the stability, to avoid 
the aggregation of lecithin-coated emulsion droplets induced by thermal 
processing, freeze-thaw cycling and high calcium ion contents, can be 
improved by coating the droplets with a polyelectrolyte (25-26). Layer by 
layer methodology is one of the most common strategies used to obtain thin 
polymeric films around O/W NEs. 
 
 
 
1.4. Layer by Layer Methodology Applied to Multilayered 
Polymer Nanoemulsions 
 
Layer by layer technique is based on the sequential adsorption of oppositely 
charged polyelectrolytes on a charged substrate. This technique was firstly 
proposed by Iler in 1966 for the alternate assembly of oppositely charged 
layers of colloidal particles (27). The same concept was adapted 25 years 
later by Decher and co-workers that reported the fabrication of 
multicomposite films of charged materials through LbL adsorption from 
aqueous solutions (28). Since then, extensive work has been carried out on 
the application of this technique to the fabrication of ultrathin films on 
surfaces of any size and shape, ranging from flat surfaces to round template 
particles (29). A significant step for the preparation of polyelectrolyte 
nanocapsules was done by Sukhorukov et al. in 1998 that fabricated hollow 
capsules by layer-by-layer assembly of polyelectrolyte film–coated colloidal 
particles and subsequent removal of the colloidal core (30). Further, in 
recent years LbL adsorption of polyelectrolytes has resulted also a 
convenient method of formation of a shell at emulsion cores which is 
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designed to incorporate lipophilic drugs (31). The polymeric coating can be 
used to regulate the release rate of encapsulated active components in the 
nanoemulsion (32). Moreover, the shell can be easily functionalized to 
reduce the interactions between the capsules and the immune system 
(PEGylation for ‘‘stealth effect’’) and to immobilize target specific ligands 
for intelligent delivery systems. This chemistry uses a series of layer-by-
layer deposition steps of oppositely charged polyelectrolytes (33). The first 
step starts with colloidal particles carrying surface charges (e.g., a negative 
surface charge). Polyelectrolyte molecules having the opposite charge (i.e., 
polycations) are readily adsorbed to such a surface due to electrostatic 
interactions. Not all of the ionic groups of the adsorbed polyelectrolyte are 
consumed by the electrostatic interactions with the surface. As a result, the 
surface charge of the coated particle changes its sign and is now available 
for the adsorption of a polyelectrolyte of again opposite charge (i.e., a 
polyanion) (Fig. 1.4). 
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Figure 1.4 Schematic representation of LbL methodology applied on O/W 
NE. O/W NE results negatively charged due to the surfactant adsorbed on 
its surface (A). A positively charged polymer is added to the nanoemulsion 
solution determining the formation of a polymer coating around the oil 
droplets and a switch of charge of the colloidal system (B). A negatively 
charged polymer is added in order to create a second polymeric layer and 
provide a negative charge to the LbL O/W NE (adapted from ref. 33).  
 
The use of LbL assembly has a number of advantages. For example, LbL 
assembly can be performed in entirely aqueous solutions, requiring no 
exposure to organic solvents. This is important for biomolecules such as 
nucleic acids and proteins, which have limited solubility in non-aqueous 
solutions and are susceptible to denaturation. The size and shape of the 
capsules can be engineered by simply altering the template used for polymer 
adsorption. A large range of polymers can be used to prepare the capsule 
wall, resulting in the ability to finely tune the composition, permeability, 
stability, and surface functionality of the capsules. The assembly process is 
relatively cheap, requiring only simple laboratory equipment, and can be 
performed with inexpensive materials. For these reasons, LbL assembly is 
considered a promising method for the creation of efficient therapeutic 
delivery devices (35).  
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Herein we showed how Isothermal Titration Calorimetry is able to provide 
important information related to the LbL assembly on O/W NEs, and the 
subsequent attachment of the nanocapsules to macromolecules. 
 
 
 
1.5. Isothermal Titration Calorimetry in Nanotechnology 
 
Isothermal titration calorimetry (ITC) is a valuable method aimed at 
characterizing the energetics of molecular interactions evaluating the heat 
absorbed or released upon molecular interactions, at constant temperature 
and pressure (36). ITC is able to provide the complete thermodynamic 
profile (i.e., binding constant (Kb), enthalpy change (ΔH), entropy change 
(ΔS), Gibbs energy change (ΔG)) and the stoichiometry of interaction in a 
single experiment. In Fig. 1.5, it is represented a schematic illustration of a 
typical ITC instrument. Since this methodology has the ability to determine 
the different energetic contributions to the binding affinity without 
introduction of labels on the ligands, it can be considered the technique of 
choice for the study of complex systems where the use of a label may 
introduce artifacts. So far, ITC has been widely used to study molecular 
interactions in biological systems (e.i. protein-protein, DNA-DNA, protein-
DNA), anyway in recent years it has shown great potential in 
nanotechnology field (37) where it has been proved to be a useful tool to 
study the energetic of assembly of polymeric nanoparticles giving 
information on the thermodynamic signature of the nanodevice formation. 
Further, calorimetric analysis of nanoparticles is a growing field due to 
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ready availability of the instrumentation in core facilities and reduced 
sample requirements of modern calorimeters. In particular, ITC resulted 
extremely important to find the optimal conditions of polymer coating 
around a nanotemplate. In particular, Mertins and Dimova 
thermodynamically characterized the interaction of chitosan with small 
liposomes and the organization of the polysaccharide on the membrane of 
the vesicles. ITC was particularly important in this study for assaying the 
enthalpy changes arising from binding of the positively ionized chitosan to 
neutral and negatively charged liposomes. The equilibrium constant, the 
interaction stoichiometry, and the molar enthalpy of binding chitosan 
monomers to phospholipids from the external leaflet of the vesicle 
membrane were obtained from the isotherm curves (38). Further, ITC has 
resulted a valuable methodology to quantify the energetics of interactions of 
nanoparticles with proteins or nucleic acids. For instance, Mosquera et al. 
performed ITC experiments to understand association efficiency and loading 
capacity of insulin into the polymeric nanoparticles under different pH 
conditions and achieve the best NP system capable to simultaneously 
modulate and control the insulin delivery in order to favor the best sustained 
protein release (39). 
In this dissertation it will be illustrated how ITC can be extremely important 
in the build-up of a nanocarrier both to find the optimal conditions of 
polymer coating around the nanoemulsion and to gain information about the 
interaction between the oil in water secondary nanoemulsion and a protein. 
In the first case, we performed a complete physicochemical characterization 
to identify polymer concentration domains that are thermodynamically 
stable and to define the degree of stability through thermodynamic functions 
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depending upon relevant parameters affecting the stability itself, such as 
type of polymer coating, droplet distance, etc. This is very important to 
prolong the shelf life of products and make them suitable for a variety of 
applications ranging from nutraceutics to cosmetics and pharmaceutics. In 
the second case, we studied the interaction between the streptavidin and a 
polylysine secondary nanoemulsion functionalized with biotin. In this way 
with a simple calorimetric titration we gained information about the amount 
of functionalizable groups exposed on the nanoparticle surface. 
 
Figure 1.5 Illustration of an ITC instrument. A typical ITC instrument 
consists of two equivalent cells positioned in an adiabatic jacket. The 
temperature of each cell is monitored and maintained at a constant 
temperature through an electronic feedback loop that controls 
thermoelectric heaters located near each cell. During the experiment the 
titrant, which is in the injection syringe, is added to the sample cell. If the 
reaction is exothermic, heat evolves and the temperature of the sample cell 
increases. The feedback loop responds by reducing the power to the 
resistive heater around the sample cell to restore the differential 
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temperature between the cells to zero. This mechanism gives rise to a power 
versus time curve with more positive peaks at the beginning and gradual 
decrease of them. At saturation when no reaction is taking place, the 
baseline reproduces a constant power consumption proportional to the 
power needed to maintain the difference in temperature between the cell 
and the adiabatic jacket. Small peaks are still observed due to effects such 
as buffer dilution. On the contrary, an endothermic reaction shows negative 
initial peaks that gradually become more positive. The area under each 
peak represent the heat involved in the reaction, the integration, subtraction 
of background areas and normalization for injected moles of titrant, gives 
the enthalpy involved in the process as a function of the ratio between 
titrant and titrate concentrations. The total differential enthalpy results 
negative in exothermic reactions and positive for endothermic reactions 
(40). 
 
 
 
1.6. Thesis Purpose  
 
The first purpose of this thesis was to synthetize and characterize, from a 
thermodynamic point of view, O/W SNEs in order to obtain all the 
information needed to prolong the shelf life of the product. A new method 
based on Isothermal Titration Calorimetry was used to define the degree of 
stability depending upon relevant parameters affecting the stability itself, 
such as type of polymer coating and droplet distance. The second purpose 
was to decorate O/W SNEs with PEG chains and with a cell penetrating 
peptide in order to improve respectively its circulating time in blood stream 
and capability to cross an endothelial cell layer. Biological tests were 
conducted on the decorated O/W SNE showing a better transcytosis through 
an endothelial barrier and most importantly a much higher accumulation in 
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the endothelial barrier as compared with the non-decorated counterpart. The 
last aim of this thesis was to set up a new method able to quantify the 
amount of a specific receptor on the cells surface in order to identify targets, 
to address drug design and selectively deliver therapeutics. In this regards, 
ITC measurements coupled with confluent cell layers cultured around 
biocompatible templating microparticles were conducted to evaluate the 
number of transferrin receptors (TfRs) onto the cell membrane and study the 
energetics of their interaction with the transferrin.  
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CHAPTER 2  Thermodynamic Signature of 
Secondary Nanoemulsion by Isothermal Titration 
Calorimetry 
 
 
2.1. Introduction 
 
Oil in water nano-emulsions (O/W NEs) are being increasingly investigated 
for their ability to dissolve large quantities of hydrophobic compounds and 
protect their cargo from hydrolysis and enzymatic degradation, therefore 
improving hydrophobic drug bioavailability. This makes O/W NEs ideal 
vehicles for the purpose of drug delivery (1−6). Moreover, these colloidal 
systems can be used as multifunctional platforms, allowing for the cancer-
research-related field to benefit from simultaneous imaging and targeted 
drug delivery (7−9). In addition, O/W NEs can be suitable for gene therapy 
(10) and as the basis of many kinds of foods (e.g., milk, cream, beverages, 
dressings, etc.) (11,12), as well as cosmetics (lotions, transparent milks, and 
crystal-clear gel) (13−17). The main limitation of O/W NEs is their poor 
stability over time because they are thermodynamically unstable systems 
(18). One strategy to improve emulsion stability, proposed by McClements 
and his group, is to produce secondary emulsions obtained with a 
polyelectrolyte thin layer, adsorbed through the interaction with an ionic 
emulsifier of opposite charge standing on the surface of the starting primary 
emulsion (19). When the polymer concentration is varied, it is possible to 
control the level of polymer coating and obtain O/W NEs with increasing 
stability before the occurrence of another mechanism of aggregation, the so-
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called depletion flocculation. However, at the moment, emulsion stability is 
only evaluated experimentally or based on theoretical considerations that 
determine the level of coating. No methods have been proposed up to now 
to evaluate the stability of secondary nano-emulsions from a thermodynamic 
point of view, therefore precluding the possibility to correctly assess the 
stability of such a system. Herein, we use isothermal titration calorimetry 
(ITC) to study the evolution of the polymer deposition around primary 
nano-emulsions and obtained novel results regarding thermodynamic 
stability domains. Thus far, ITC has been widely used to study molecular 
interactions in biological systems and only in a few cases applied to 
nanosystems (20−26). Particularly, Mertins and Dimova employed ITC to 
observe the interaction of chitosan with zwitterionic liposomes organized in 
vesicles. They described the thermodynamic parameters of the overall 
adsorption process by a single binding event; the liposome aggregation was 
mainly detected by dynamic light scattering (DLS) measurements. In our 
study, for the first time, we investigated in depth the binding between a 
primary nanoemulsion and a polyelectrolyte using a state-of-the-art nano-
ITC technique, gaining information on the thermodynamic signature of two 
well-defined adsorption events. A third event was also detected by ITC and 
attributed to an aggregation phenomenon. Polyelectrolytes of two different 
classes were chosen to explore the validity of our approach: chitosan, a 
polysaccharide, and poly-L-lysine, a polypeptide. ITC provided useful 
information on the strength of the adsorption in terms of thermodynamic 
functions, for both systems. In addition, for what concerns the level of 
polymer coating around primary emulsions, we showed herein that, after a 
first saturation, a complete coating of the droplets is only possible at much 
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higher concentrations; the saturation method, conversely, is based on ζ-
potential measurements and provides the saturation condition by identifying 
the ζ-potential plateau (27). The two distinct events were completely 
characterized and quantified in terms of thermodynamic parameters. For this 
purpose, two different sets of ITC measurements were designed ad hoc. The 
precise evaluation of the level of polymer coating around primary emulsions 
is very useful when the emulsion has to be used as a template for the 
preparation, via layer by layer, of polymer nanocapsules, very promising as 
multifunctional nanocarriers in nanomedicine (27−29). Further, the ITC 
enabled a clear understanding of when the flocculation starts, allowing for 
the achievement of the best conditions for an optimal coating. 
 
 
 
2.2. Materials and Methods 
 
2.2.1. Sample Preparation 
 
Chitosan low molecular weight [CT-LMW, 127 kDa, degree of 
deacetylation (DD) = 84%] and poly-L-lysine (PLL, 4−19 kDa) were 
purchased from Sigma-Aldrich. Chitosan solution was prepared dissolving 
10 mg in 1 ml of 0.1 M acetic acid solution (pH 3) by vigorous stirring 
overnight; the obtained solution was then filtrated. Chitosan solutions at 
different concentrations were obtained diluting the bulk solution with 0.1 M 
acetic acid solution at pH 4 to be able to dissolve chitosan; PLL solutions 
were prepared by dissolving 50 mg in 1 ml of Milli-Q water (final pH 6.0). 
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First, a 10 wt % oil in water pre-emulsion was prepared by dissolving the 
surfactant (egg lecithin) in the oil phase (soybean), stirring the sample for 40 
min at 60 °C and 180 revolutions per minute (rpm) speed, and then 
performing sonication runs of 10 s for 1 min at 60% of the sonication 
amplitude. Then, the oil phase was added to the aqueous phase, 5 mL at a 
time, and mixed using an immersion sonicator with runs of 10 s for 8 min. 
The pre-emulsion was finally homogenized for 3 single cycles and 200 steps 
at a pressure of 1330 bar by a high-pressure homogenizer (110P series 
microfluidizer) to obtain the final nano-emulsion (180−200 nm, ∼−30 mV, 
pH 4.3). Soybean oil and fat-free egg lecithin with 80 wt % 
phosphatidylcholine (Lipoid E80) were purchased from Lipoid. In some 
preparations, we needed higher oil concentrations; therefore, we also 
prepared a O/W NE at a concentration of 20 wt % (2000 bar), keeping the 
same lecithin/oil ratio to obtain about the same size. All of the steps of the 
process were the same as described for the 10 wt % O/W NE. The first 
positively charged layer of polymer (chitosan or PLL) was obtained by 
adding in one shot the polymer solution to the emulsion solution under 
vigorous stirring (1500 rpm). The second layer was obtained in the same 
way by adding the negatively charged polymer to the positively charged 
secondary nano-emulsion. 
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2.2.2. ζ-Potential Measurements. 
 
ζ-Potential titration experiments were performed by a Malvern Zetasizer. In 
this technique, a voltage gradient is applied across a pair of electrodes of the 
cell containing the particle dispersion. Charged particles are attracted to the 
oppositely charged electrode, and their velocity can be measured and 
expressed in unit field strength as an electrophoretic mobility. ζ-potential is 
the electrostatic potential that exists at the interface of the nanoparticle, 
which is related to both the surface charge and the local environment of the 
particle. It was automatically calculated from the electrophoretic mobility 
based on the Smoluchowski equation, ν = (εE/η)ζ, where ν is the measured 
electrophoretic velocity, η is the viscosity, ε is the electrical permittivity of 
the electrolytic solution, and E is the electrical field. In these titration 
experiments, different samples were prepared varying the concentration of 
chitosan or PLL in water, expressed as a weight/weight percent, from 0 to 
0.020 wt % and keeping constant the weight/weight percent O/W NE at 1 wt 
%. Before each experiment, 50 μl aliquots were withdrawn from each 
sample and diluted 1:40 (v/v) with 20 mM acetic acid solution at pH 4 for 
chitosan-based secondary nano-emulsions or Milli-Q water at pH 6 for PLL-
based secondary nano-emulsions. The diluted samples were poured into 
disposable cells, and the ζ-potential was determined at least 3 times for each 
sample. Measurements were recorded at 25 °C. ζ-potential values were 
plotted as a function of the weight ratio between polymer (chitosan or PLL) 
and O/W NE. Each titration experiment was performed 3 times; the errors 
on ζ-potential values were calculated on three measurements. 
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2.2.3. Nano-emulsion Size Measurements 
 
Nano-emulsion size measurements were also performed by a Malvern 
Zetasizer. In particular, the particle size distribution was measured by laser 
DLS (λ= 632.8 nm). This technique correlates the fluctuations of scattered 
light intensity I(t) during time with the Brownian motion of colloidal 
particles associated with the diffusion coefficient D, which is related to the 
hydrodynamic radius Rh of the particles. A detecting angle of 173° was 
used. All samples were diluted up to a droplet concentration of 
approximately 0.025 wt % using Milli-Q water in the case of primary 
emulsions; PLL-based secondary emulsions and an acetic acid Milli-Q 
water solution (pH 4, 20 mM) were used in the case of chitosan-based 
secondary emulsions. A default refractive index ratio (1.52) and three 
measurements of 5 runs (1 run lasting 100 s) were used in the calculations 
of the particle size distribution. 
 
2.2.4. Isothermal Titration Calorimetry 
 
ITC experiments were performed using a nano-ITC low volume calorimeter 
(TA Instruments) equipped with a reference and sample cell of 170 μl. All 
titrations were carried out at 25 °C using a 50 μl syringe at a stirring rate of 
250 rpm. The sample cell was always filled with the O/W NE, and the 
reference cell was always filled with Milli-Q water. All solutions were 
degassed for 5 min before starting the experiments to eliminate air bubbles. 
The pH of each solution was monitored before experiments to ensure the 
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same values in the cell and in the syringe. The pH was adjusted when 
required. Two sets of ITC experiments were performed. In the first set, the 
titration experiments were performed by a single injection of 50 μl of 
chitosan at a concentration from 0.01 to 0.08 wt % or PLL at a 
concentration from 0.01 to 0.06 wt % into the reaction cell filled with 1.34 
wt % O/W NE to have a final emulsion concentration of 1 wt %. The 
relative amount of polymer and nano-emulsion was expressed in terms of 
the ratio (R) between the concentration of chitosan or PLL and the 
concentration of nano-emulsion, both expressed as a weight percentage. The 
comparisons between the two polymers were made in the R range between 
0.003 and 0.018. The heat released for each injection was evaluated over 
1200 s. In the second set, higher values of R (between 0.018 and 0.27) were 
evaluated by stepwise titration experiments with 25 aliquots of 2 μl of 
chitosan or PLL solution at 1 wt % injected with 200 s intervals into the 
working cell filled with 1.1 wt % O/W NE, to link the last concentration of 
the single-injection experiment with the first concentration of the stepwise 
titration experiment. The time interval between two consecutive injections 
was chosen to reach the thermodynamic equilibrium before the next 
injection. In the case of PLL, the same experiments were also conducted at 
two more different concentrations of nano-emulsion (∼5 and ∼10 wt %). In 
particular, single-injection titration experiments were conducted by injecting 
50 μl of PLL from 0.044 up to 0.33 wt % into the reaction cell filled with 
6.5 wt % O/W NE or injecting 50 μl of PLL from 0.088 up to 0.79 wt % 
into the reaction cell filled with 13 wt % O/W NE, depending upon the final 
concentration of nanoemulsion (5 and 10 wt %, respectively). The heat 
released for each injection was evaluated over 1200 s. Ratios between 0.003 
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and 0.019. were explored, and then higher values of R were evaluated by 
injecting stepwise 25 aliquots of 2 μl of 2.5 or 5 wt % PLL solution, with 
200 s intervals, into the working cell filled with 5.1 or 10.2 wt % O/W NE, 
respectively. Heat produced by chitosan or PLL dilution was evaluated by 
performing a control experiment, titrating each polymer into the buffer 
alone. The interaction heat for each injection was calculated after correction 
for the heat coming from polymer dilution. The resulting corrected injection 
heats were plotted as a function of the weight ratio between polymer and 
O/W NE concentrations, fitted with a model for one set of binding sites and 
analyzed with a nonlinear least-squares minimization algorithm, using the 
program NanoAnalyze software, version 2.4.1 (TA Instruments). ΔbH° 
(binding enthalpy change in kJ mol−1), Kb (binding constant in M−1), and 
stoichiometry (N = binding sites, calculated at the inflection point as the 
ratio between polymer and O/W NE concentrations) were the fitting 
parameters. The Gibbs energy and entropy change contributions were 
calculated using the relationships: 
 ΔbG° = −RT ln Kb, (R = 8.314 J mol
−1
 K
−1
, and T = 298 K)  
 TΔbS° = ΔbH° − ΔbG°. 
The errors on the heat of the single titration experiments were calculated on 
the average of three measurements. The errors on thermodynamic 
parameters Kb, ΔbH°, and stoichiometry were based on the percentage of 
confidence of the fitting procedure, and the errors on ΔbS° and ΔbG° were 
derived by the theory of error propagation. 
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2.3. Results and Discussion 
 
Polymer coatings around primary emulsions are typically studied by 
measuring the ζ-potential. In particular, there is a switch in the ζ-potential of 
the colloidal system when the polymer is added a little at a time. A plateau 
in the ζ-potential is associated with the saturation of the surface by means of 
the polymer coating. We performed the ζ-potential as a reference analysis; 
to gain a deeper insight in the stoichiometry of layer by- layer interactions 
and to analyze the energetics of nanoparticle assembly, we carried out ITC 
experiments. The methodology is based on the measurement of the heat 
absorbed or released following titration through injecting a solution of one 
of the interacting molecules (the ligand) into a cell containing a solution of 
the other molecule (a macromolecule). 
 
 
 
2.3.1. ζ-Potential Analysis 
 
The ζ-potential of the O/W NE was negative (ζ = −35.4 mV) in the absence 
of chitosan, which can be attributed to the presence of charged carboxylic 
acid groups along the lecithin chain. When the chitosan concentration is 
increased, the ζ-potential initially became increasingly less negative, with a 
point of zero charge at around 0.00023 wt % chitosan, and reached a plateau 
for higher concentrations (Fig. 2.1A). The saturation ratio was reached at 
around 0.01 wt %. In the case of PLL, the same emulsion formulation was 
used (ζ = −31.2 mV). The point of zero charge was reached at around 
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0.0011 wt %, with the saturation concentration at around 0.01 wt % (Fig. 
2.1B). However, no indications about the affinity between polymers and 
primary emulsion can be registered through the ζ-potential analysis. 
Moreover, because the ζ-potential is highly sensitive to the environmental 
conditions, slight differences in the ion concentration can affect 
measurements, which are typically scattered, making it difficult to assess the 
concentration at which the plateau is reached. 
 
 
 
2.3.2. Isothermal Titration Calorimetry Analysis 
 
The switching of the charge after polymer addition to the primary emulsion 
can be attributed to chitosan or PLL adsorbed on negatively charged oil 
nanodroplets, giving rise to secondary emulsions, whose stability is reached 
at well-defined values of ζ-potential, where the plateau starts. An 
understanding of the forces driving the self-assembly at the interface 
requires a comprehensive account of the thermodynamic parameters (ΔH° 
and ΔS°). Here, we employed ITC to measure the equilibrium adsorption 
constant, enthalpy of adsorption, and adsorption stoichiometry. The ITC 
measurements show that a more complex interaction than just electrostatic 
interaction occurs for both systems and gives information on the 
stoichiometry and affinity constant as well as enthalpy changes in the 
interacting molecules. In particular, the ITC analysis allowed for the 
identification of two binding events, followed by an aggregation event. The 
two binding events were not completely resolved in a single titration 
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experiment, which comprise two significantly different ratios of 
concentrations. Thus, to better characterize and separate these different 
binding events, two sets of experiments were designed, as described in the 
Materials and Methods. Briefly, in the first experiment, a set of single 
injections was accomplished in the range of R values of 0.003− 0.018; in the 
second experiment, a typical titration experiment was performed in the 
range of R values between 0.018 and 0.27. Panels C and D of Fig. 2.1 and 
Fig. 2.2 are thermograms for the binding of chitosan or PLL to the O/W NE 
at 25 °C, along with the integrated heats and the corresponding best fit 
binding models for each system. The thermodynamic data are collected in 
Table 2.1. The binding constants are always higher for the first event with 
respect to the second event; in the case of PLL, the affinity is stronger than 
that of chitosan. Table 2.1 shows that the I event is characterized by an 
exothermic binding and ΔH° values are smaller for chitosan and greater for 
PLL. The II event is almost athermic in the case of chitosan and exothermic 
for PLL, with a low ΔH° value. In both systems, the binding is 
accomplished by a favorable ΔS°, indicating that both the I and II events are 
entropically driven.  
The thermodynamic signatures are shown in Fig. 2.3. The first event can be 
mainly attributed to the predominant electrostatic interactions between the 
negative charges of the nano-emulsion and the positive charges of chitosan 
or PLL. This event, as already seen, is characterized by a favourable 
enthalpic contribution, higher for PLL/nano-emulsion interactions. In any 
case, the binding is also entropically favoured, probably because of the 
release of ordered water by the hydration shells around the positive and 
negative charges in disordered bulk water as well as counterion release after 
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the binding process (30,31). The second binding event may involve both the 
backbone and the charged groups of the molecules; the resulting low values 
of the enthalpy reflect the balance of different endothermic and exothermic 
contributions. However, the binding is entropically driven also for this 
second event, and the conformational rearrangements of chitosan or PLL 
chains play a fundamental role in the overall energetic balance, together 
with the counterion release and the water molecules of solvation released to 
the bulk water. The entropic gain consequent to a polyelectrolyte deposition 
has already been reported in the literature (25,32,33). The two binding 
events are followed by a third event, which is due to an aggregation 
phenomenon centred at about N = 0.2 for both chitosan (Fig. 2.2C and Table 
2.1) and PLL (Fig. 2.2D and Table 2.1). This third event is characterized by 
an endothermic enthalpy change and is attributed to a depletion flocculation, 
which was already described as entropically favorable but enthalpically 
unfavourable (34). The classic interpretation in terms of an entropydriven 
phenomenon is based on the Asakura−Oosawa model that describes the 
interaction energy on the basis of geometric analysis (35,36). The model 
assumes that two spherical participles are dispersed in a solution of rigid 
spherical polymer coils. The theory predicts that the addition of a small 
amount of polymer to a sterically stabilized nano-emulsion can lead to 
flocculation. The Gibbs energy is then calculated on the simplified approach 
for hard-sphere models. In particular, the increase in the entropy of the 
system is explained in terms of excluded volumes of hard spheres 
overlapping with the resulting increase in the total volume available to the 
polymer chains, which allows them greater translational freedom and, 
consequently, lowers the Gibbs energy. Overall, the thermodynamic data 
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show a first stronger binding event dominated by electrostatic interactions 
(panels C and D of Fig. 2.1) and a second weaker binding event where a 
number of interactions, such as hydrophobic, electrostatic, and polymer 
chain conformational rearrangements, compact chitosan (or PLL) coating on 
the nano-emulsion surface, stabilizing the secondary nano-emulsion. 
Finally, the depletion flocculation happens at higher polyelectrolyte 
concentrations (panels C and D of Fig. 2.2). ζ-Potential measurements only 
give a picture of the overall binding event; ITC finely distinguishes among 
three consecutive events. 
 
 
Fig 2.1 ζ-Potential data for 1 wt % O/W NE titrated with (A) chitosan or (B) 
PLL at 25 °C. ITC data for the titration by single injection of (C) chitosan 
or (D) PLL into 1 wt % O/W NE at 25 °C. R is the ratio between the 
concentration of chitosan or PLL and the concentration of nano-emulsion, 
both expressed as weight percentage. The bars correspond to the errors. 
The red lines represent the best fit obtained with the independent-site model. 
43 
 
 
 
 
Figure 2.2 ITC data for titration by stepwise injections of (A and C) 
chitosan or (B and D) PLL into 1 wt % O/W NE at 25 °C. (A and B). Heat 
flow and respective integrated binding heat corrected for dilution heat are 
plotted as a function of R. The solid curves fit according to the independent-
site model. The inset in panel C represents the zoom of the first part of the 
curve. 
 
 
Figure 2.3 Schematic diagram presenting the thermodynamic signature for 
(A) titration by single injection of chitosan and titration by stepwise 
injection of chitosan or (B) titration by single injection of PLL and titration 
by stepwise injection of PLL. 
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Previous studies carried out in our laboratory showed that secondary nano-
emulsions with very prolonged stability can be obtained only after reaching 
this second event possibly because of a more compact coverage of the 
emulsion (27). Therefore, an ITC study not only confirms the complete 
coating after the second event but also gives a deeper insight on the 
thermodynamics of the nanocapsule formation. The final saturation ratio is 
approximately the same (N = 0.1) for the two systems, but the comparison 
between the binding constants for the two systems highlights which couple 
emulsion−polyelectrolyte provides the stronger association. In the present 
study, PLL showed stronger association than chitosan, reflected on all of the 
thermodynamic parameters and, in particular, the Gibbs energy values. Such 
behavior could be due to steric hindrance, resulting from the relatively lower 
flexibility of chitosan compared to that of PLL, whose absorption is more 
effective on the nano-emulsion. Indeed, in a previous study, the chitosan 
molecules were defined “rather stiff” (37); in quantitative studies of the 
interaction between alginate and chitosan compared to the interaction 
between alginate and PLL, the faster binding of PLL was attributed to its 
higher flexibility (38). As a proof of the difference in the affinity between 
the two polymers with the nano-emulsion, some experiments were 
performed by varying the pH and depositing a bilayer of heparin, as shown 
in Fig. 2.4. 
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Figure 2.4 (A and B) Size and ζ-potential data of a heparin bilayer made on 
a chitosan monolayer at pH 4 (standard conditions) compared to the same 
made at pH 12 and dialyzed until pH 4. (C and D) Size and ζ-potential data 
of a heparin bilayer made on a PLL monolayer at pH 7 (standard 
conditions) compared to the same made at pH 12 and dialyzed until pH 7. 
 
A layer of heparin was deposited first on a monolayer of chitosan (pH 4) 
and then on a monolayer of PLL (pH 7) without modifying the pH of the 
monolayer. In both cases, we obtained bilayer nanoparticles with good 
values of size, polydispersity index (PDI), and ζ-potential. In particular, the 
size of the bilayer was quite similar (around 200 nm), as reported in panels 
A and C of Fig. 2.4. The same experiments were conducted after raising the 
pH of the monolayers to 12. In these conditions, chitosan and PLL invert 
their charge. As a consequence, the chitosan monolayer shows an increase 
in size and PDI values, possibly because of the separation of the polymer 
from the nano-emulsion and/or the formation of some bridges between 
adjacent droplets. On the contrary, the PLL monolayer preserves good 
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values of size and PDI, showing no destabilization. Then, after modification 
of the pH of the two secondary nano-emulsions, heparin was added as a 
second layer; a dialysis was conducted to reach the pH at which chitosan 
and PLL are again positively charged (pH 4 in the case of chitosan and pH 7 
in the case of PLL). The data show larger sizes and PDI and lower ζ-
potential values for the heparin−chitosan bilayer (panels A and B of Fig. 
2.4) than the values obtained for the heparin−PLL bilayer (panels C and D 
of Fig. 2.4) because of the starting destabilization of the chitosan-based 
secondary emulsions at pH 12. These results proved that, as also shown by 
ITC, PLL deposition on O/W NE is stronger than that of chitosan. It was 
actually so strong as to be stable against the repulsion phenomenon 
established between polymer and oil−lecithin at pH 12. 
 
 
 
2.3.3. Isothermal Titration Calorimetry Analysis of PLL 
Interactions with Different O/W NE Percentages 
 
PLL showed a higher affinity for the nanoemulsion than chitosan. The 
following step was to prepare PLL-based secondary O/W NEs at different 
oil concentrations. Specifically, 5 and 10 wt % were compared to the 1 wt % 
O/W NE to check their ability to interact with PLL. For these experiments, 
we started from the 20 wt % O/W NE (size, 178 nm; PDI, 0.028; and ζ 
potential, −47 mV). The same two sets of ITC measurements described 
above were performed: a single-injection experiment was made to study the 
first binding event (Fig. 2.5), and a typical titration experiment was 
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accomplished to study the second binding event and third event because of 
depletion flocculation (Fig. 2.6).  
 
 
Figure 2.5 ITC data for titration by single injection of PLL into (A) 1 wt % 
O/W, (B) 5 wt % o/w, and (C) 10 wt % O/W NE at 25 °C. The solid squares 
are the experimental data obtained by integrating the raw data and 
subtracting the heat of PLL dilution into the buffer. The bars correspond to 
the errors on the data. The red lines represent the best fit obtained with the 
independent-site model. 
 
 
Figure 2.6 ITC data for titration by stepwise injection of PLL into (A) 1 wt 
% O/W, (B) 5 wt % O/W, and (C) 10 wt % O/W NE at 25 °C. The solid 
squares are the experimental data obtained by integrating the raw data and 
subtracting the heat of PLL dilution into the buffer. The red lines represent 
the best fit obtained with the independent-site model. 
48 
 
The thermodynamic parameters are collected in Table 2.1. Interestingly, the 
first event (previously referred to as predominant electrostatic interactions 
between PLL and the nano-emulsion) is centered at the same N value for all 
of the oil in water percentages, but the second and third events show 
decreasing N values and increasing oil in water percentage. Another 
interesting result is that the enthalpy of the first event becomes more 
favourable at increasing oil in water percentages, whereas the entropic 
contribution inverts its sign and becomes unfavourable. Indeed, all types of 
interactions are water mediated, and when the water content decreases, 
electrostatic interactions are favoured because the water-charged group 
competition is reduced. This phenomenon is enthalpically favourable. 
Moreover, the water content decrease in the nanoemulsion significantly 
varies the extension of ordered water molecules in the hydration shells of 
the charged groups and gives a minor contribution to the overall entropy of 
binding given that the charged groups are partially dehydrated prior to 
binding. The binding constants remain unaffected by the increase in the oil 
in water percentage. However, the result that appears noteworthy for 
practical applications is that the complete coating, referred to the second 
events, occurs closer and closer to the first event at increasing oil in water 
percentages, as shown in Table 2.1. The same happens for the third event, 
associated with flocculation, which also occurs closer and closer to the 
second event at increasing oil in water percentages (Table 2.1). These 
findings suggest very precisely the range of stability of a secondary nano-
emulsion in relation to the final concentration of the dispersion, and at the 
same time, they provide the thermodynamic signature of all of the 
interactions. 
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Table 2.1 Thermodynamic parameters of the interaction between chitosan 
or PLL and O/W NE at 1, 5, and 10 wt %. 
 
 N Kb 
ΔH° 
(kJ mol
-1
) 
TΔS° 
(kJ mol
-1
) 
ΔG°(298K) 
(kJ mol
-1
) 
Chitosan 
1% 
O/W 
I 
event 
1.1± (0.1) x10
-2
 
9.2±(0.5) 
x10
5
 
-1.1±0.2 32.9±4.0 -34.0±3.8 
II 
event 
9.9± (0.5) x10
-2
 
5.2± (0.2) 
x10
4
 
0.20±0.02 27.1±3.2 -26.9±2.4 
III 
event 
22.0± (1.1) x10
-2
 
2.0± (0.1) 
x10
4
 
1.3±0.1 25.8±3.1 -24.5±2.0 
Poly-L-lysine 
1% 
O/W 
I 
event 
1.0±(0.1) x10
-2
 
6.1± (0.5) 
x10
7
 
-21.5±2.0 22.9±2.8 -44.4±4.5 
II 
event 
10.4±(0.6) x10
-2
 
2.9± (0.1) 
x10
6
 
-1.9±0.1 34.9±3.5 -36.8±3.0 
III 
event 
21.0±(1.1) x10
-2
 
6.0± (0.5) 
x10
4
 
2.6±0.1 29.8±2.8 -27.2±2.1 
       
5% 
O/W 
I 
event 
1.0± (0.1) x10
-2
 
5.2± (0.5) 
x10
7
 
-50.0±6.0 -6.0±0.8 -44.0±5.0 
II 
event 
7.0±(0.4) x10
-2
 
2.8± (0.1) 
x10
6
 
-3.7±0.3 33.1±3.4 -36.8±2.9 
III 
event 
11.0±(0.6) x10
-2
 
2.8± (0.1) 
x10
4
 
2.0±0.1 27.4±2.8 -25.4±2.0 
       
 10 
% 
O/W 
I 
event 
0.9±(0.1) x10
-2
 
2.0± (0.2) 
x10
7
 
-122±10 -80.4±10.4 -41.6±4.2 
II 
event 
6.0±(0.5) x10
-2
 
2.0± (0.1) 
x10
6
 
-3.5±0.3 32.5±3.4 -36.0±2.9 
III 
event 
9.2±(0.5) x10
-2
 
3.0± (0.1) 
x10
4
 
2.3±0.1 27.8±2.9 -25.5±2.1 
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2.4. Conclusions 
 
ITC was employed for the first time to study the optimal conditions for 
nano-emulsion coating. ITC measurements on the layer-by-layer 
interactions are rapid, accurate, and informative and constitute a substantial 
added value if compared to information derived from ζ-potential 
measurements. ITC data allowed for the acquisition of the thermodynamic 
signature of the investigated systems and the dissection of the Gibbs energy 
into entropic and enthalpic contributions. In particular, we found that the 
O/W NE/ polyelectrolyte structures are entropically driven. The entropic 
driving force may be explained as a result of several contributions: the 
release of ordered water from the hydration shells of the two interacting 
partners to the bulk water upon the direct interactions, the counterion 
release, the conformational rearrangements of polymeric chains, and the 
hydrophobic interactions. Calorimetric measurements proved that 
complementary and more accurate information than ζ-potential 
measurements can be obtained on layer-by-layer interactions between 
polyelectrolytes and O/W NEs; on the basis of the knowledge of the 
energetics of the interactions, we were able to identify the binding strength 
of chitosan and PLL with lecithin O/W NEs. In addition, in comparison of 
ITC to ζ-potential analysis, it was possible to detect two separate binding 
events, instead of just one saturation event. It confirms previous results 
regarding the dependence of secondary emulsion stability on the level of 
coating and allows to understand the increase of stability with the oil 
concentration. For the purpose of identifying the two different binding 
events, a combination of two sets of ITC experiments was for the first time 
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designed and carried out. Moreover, ITC accurately defines when 
flocculation starts, allowing for a fine modulation of the O/W NE 
percentage and the achievement of the optimal conditions for their use. 
Finally, the knowledge of the energetics of overall interactions may help to 
select the coating that guarantees the best performance in the field of drug 
administration. 
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CHAPTER 3   Synthesis and Characterization of 
Bioactive Conjugated O/W Secondary Nanoemulsions 
for Drug Delivery 
 
 
3.1. Introduction 
 
The vascular endothelium lines the inner surface of blood vessels. It is the 
first interface between circulating blood and surrounding extravascular 
tissues (1). Vascular endothelium not only regulates blood delivery and 
perfusion but also provides a semipermeable barrier that controls blood–
tissue exchange of fluids, nutrients, and metabolic wastes (2). 
Unfortunately, this fundamental organ can be affected by different types of 
dysfunction which can occur during different inflammation states or tumors. 
Vasculitis provides an example of vascular endothelium inflammatory 
disease (3). The exact cause of vasculitis is not fully understood. Some 
types are related to a person's genetic makeup. Others result from the 
immune system attacking blood vessel cells by mistake. The pathology 
causes changes in the walls of blood vessels, including thickening, 
weakening, narrowing and scarring. These changes restrict blood flow, 
resulting in organ and tissue damage (Fig. 3.1). Depending on the type of 
blood vessel that is affected (small, medium, or big sized vessel) different 
types of vasculitis have been identified (5,6). Drugs used to treat vasculitis 
include corticosteroids to control inflammation (prednisone or 
methylprednisolone) and immune-suppressants that decrease the function of 
immune system cells causing the inflammation (azathioprine, methotrexate 
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and cyclophosphamide) (7). Another example of vascular endothelium 
dysfunction is represented by angiogenesis which is the growth of new 
vessels from pre-existing vasculature that supply oxygen and nutrients to 
proliferating tumor cells (8). In normal physiological circumstances, 
angiogenesis is well controlled by pro- and anti-angiogenic factors. Though, 
in cancer, this balance is disturbed because tyrosine kinases, that are pro-
angiogenic factors are over-expressed. In the past two decades, inhibitors of 
angiogenic tyrosine kinases receptors have been developed as a systemic 
treatment strategy for cancer (9,10). 
In this work, we synthetized and characterized a biodegradable O/W SNE 
decorated with PEG chains and the peptide gH-(625-644) able to 
accumulate in the endothelium barrier and sustainably release its lipophilic 
cargo making possible therapy of the endothelium layer or drug release from 
the layer to the tissue. The incorporation of lipophilic drugs in O/W NEs is a 
smart way to overcome the solubility problems. A great deal of research is 
ongoing on this field especially because many of the newly discovered 
drugs have a low solubility in water (11). Nanoemulsions present high 
solubilization capacity of hydrophobic drugs, ease of production, long-term 
stability, ability to reduce the toxicity of cytotoxic drugs, and ability to 
protect drugs from hydrolysis and enzymatic degradation under 
physiological conditions which make them promising drug delivery systems 
(12). A number of drug-containing nanoemulsion formulations have been 
already introduced in the pharmaceutical market and several others are 
under preclinical and clinical stage of development (13). Anyway, it is 
known that cationic surface charges on nanoparticles, support better the 
transfer through negatively charged bio-membranes (14). For this reason we 
60 
 
prepared an O/W SNE through the deposition of a positively charged 
polyelectrolyte, poly-L-lysine, where electrostatic forces facilitate layer 
build-up. This strategy appears also as the main way to improve 
nanoemulsion stability (15). On the other hand phagocytosis by the 
mononuclear phagocyte system (MPS) is unfortunately higher for positively 
charged particles. To inhibit the clearance of positively charged 
nanoparticles, we decorated them with poly(ethylene glycol) (PEG) chains. 
PEG is a coiled polymer of repeating ethylene ether units with dynamic 
conformation (16). The movement of PEG chains conjugated on 
nanoparticles reduces MPS uptake and association with non-targeted serum 
and tissue proteins. Due to this attribute, PEGylated nanoparticles generally 
have an increased circulation time in blood stream and accumulate in the 
liver a half to a third of the amount of non-PEGylated nanoparticles (17). 
Further in order to enhance the nanocapsules entrance in endothelium 
barrier, we functionalized them with the peptide gH-(625-644) which is able 
to merge the cellular membranes. It was diffusely demonstrated that the 
peptide gH-(625-644), previously identified as a membrane-perturbing 
domain in glycoprotein H (gH) of herpes simplex virus 1, is able to traverse 
the membrane bilayer (18). gH-(625-644) once bound to membranes tends 
to adopt a stable-helical conformation characterized by a strong amphipathic 
propensity since one side is constituted by aromatic and hydrophobic 
residues, whereas the other side is formed by hydrophilic or small residues. 
This characteristic enables the peptide to associate and fuse with the 
membrane (19). In vitro studies on a model of endothelial barrier showed 
that conjugation of gH625 to the surface of polystyrene nanoparticles 
enhances their transport across the endothelial cells (20).  
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In this work, we synthetized and characterized step by step PEGylated 
nanocapsules (NCs) decorated with the gH-(625-644) peptide which allows 
them to escape the endocytic pattern. We also demonstrated that differently 
from studies done on rigid nanoparticles a consistent amount of NCs 
accumulates in the endothelium vessel with consequent possibility to release 
its cargo over the time and treat the endothelial barrier dysfunction attacking 
from the inside of the cells. 
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Figure 3.1 shows a normal artery with normal blood flow. The inset image 
shows a cross-section of the normal artery. Figure B shows an inflamed, 
narrowed artery with decreased blood flow. The inset image shows a cross-
section of the inflamed artery. Figure C shows an inflamed, blocked 
(occluded) artery and scarring on the artery wall. The inset image shows a 
cross-section of the blocked artery. Figure D shows an artery with an 
aneurysm. The inset image shows a cross-section of the artery with an 
aneurysm (4). 
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3.2. Materials and Methods 
 
3.2.1. Polylysine Functionalization with Biotin 
 
Biotin (0,224 mmol) was solubilized in 25 ml N,N-dimethilformamide 
(DMF). PLL (0,0448 mmol), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC) (0,224 mmol) end N-hydroxysuccinimide (NHS) 
(0,112 mmol) were added to 5 ml of carbonate buffer. The two solutions 
were mixed and the reaction was carried on for 6 h adding other EDC (0,224 
mmol) after the first hour. The product was lyophilized, solubilized in 
water, centrifuged and then dialyzed. All the reagents and solvents were 
purchased from Sigma Aldrich. Nuclear Magnetic Resonance (NMR) 
spectra were recorded using an Agilent 600 MHz (14 T) spectrometer 
equipped with a DD2 console and a One NMR HX probe. PLL and PLL-
biotin samples (1 mg) were dissolved in 600 µl of 90/10 H2O/D2O solution. 
1H 1D spectra were recorded at 300 K using 1024 scans to obtain a good 
signal-to-noise ratio. Water signal was reduced using a PRESAT pulse 
sequence. Spectra were transformed and analysed using VNMRJ4 software. 
Chemical shift scale was referenced to the solvent residual peak signal. 
3.2.2. Peptide Synthesis and PEGylation 
 
gH625 peptide was synthesized in a modified version, with a spacer of three 
glycine residues from the C-terminal amino acid, a cystein residue, and with 
a β-alanine at the N-terminal. Briefly, synthesis was performed on a fully 
automated multichannel peptide synthesizer Biotage Syro Wave. It was 
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assembled on a rink-amide resin (0.71 mmol/g; Sigma Aldrich) using 
fluorenylmethyloxycarbonyl (Fmoc) solid-phase peptide synthesis. 
Activation of Fmoc-protected amino acids was achieved using 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate: 
hydroxybenzotriazole: N,N-diisopropylethylamine (HBTU:HOBt:DIEA) 
(1:1:2). Fmoc deprotection was carried out using 20% piperidine in DMF. 
All couplings were performed for 15 min and deprotections for 10 min. The 
entire synthesis was conducted under microwave (Mw) treatment. The 
following protecting groups were used: Trt (Asn), tBu (Ser, Thr, Tyr), Boc 
(Trp), Mmt (Cys). The N-terminal was then conjugated to fluorescein 
isothiocyanate (1:3) using DIEA (1:6). The 4-methoxytrityl protector group 
(Mmt) was removed selectively from the lateral chain of the cystein residue 
using trifluoroacetic acid/triisopropyl-silane/dichloromethane 
(TFA/TIS/DCM) (1:2:97). The –SH free group was conjugated to the 
malemide group of biot-PEG2000-Mal (NanoCS) (1:2) under Mw for 4h at 
50°C in N,N-diisopropylethylamine/dimethylformamide (DIEA/DMF) (pH 
8-9), 0,1 mM tris-(2-carboxyethyl)-phosphine hydrochloride (TCEP). 
PEGylated peptide was removed from the resin, by treatment with a 
TFA/TIS/H2O (90:5:5, v/v/v) mixture for 90 min at room temperature, then 
precipitated in cold diethyl ether, dissolved in a water/acetonitrile (1:1, v/v) 
mixture, and lyophilized. Products were purified by reversed-phase high 
performance liquid chromatography (RP-HPLC) using a Waters 2535 
Quaternary Gradient Module, equipped with a 2489 UV/Visible detector 
and with an X-Bridge BEH300 preparative 10× 100 mm C8, 5μm column 
and applying a linear gradient of 0.1% TFA in acetonitrile (CH3CN)/ 0.1% 
TFA in water from 30% to 95% over 30 min at flow rate of 5 ml/min. The 
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negative control sequence was synthetized, PEGylated and purified in the 
same way. PEGylated peptide purity and identity were confirmed by LC-
MS (Agilent 6530 Accurate-Mass Q-TOF LC/MS spectrometer). Zorbax 
RRHD Eclipse Plus C18 2.1 x 50 mm, 1.8 µm columns were used for these 
analyses. 
Reagents for peptide synthesis (Fmoc-protected amino acids, resins, 
activation, and deprotection reagents) were from Iris Biotech GMBH. 
Solvents for peptide synthesis and HPLC analyses were from Sigma 
Aldrich; reversed phase columns for peptide analysis were supplied from 
Waters. Circular dichroism (CD) spectra curves were recorded on a Jasco-
1500 circular dichroism spectrophotometer in a 0.2 cm path length cuvette 
and the wavelength was varied from 190 to 260 nm. A time constant of 4 s, 
a 2 nm bandwidth, and a scan rate of 20 nm/min were used to acquire the 
data. The spectra were signal-averaged over at least three scans and baseline 
corrected by subtracting a water spectrum. 
 
 
 
3.2.3 NCs Preparation 
 
First, a 20 wt % oil in water pre-emulsion (130-140 nm, ∼−30 mV, pH 4.3) 
was prepared by dissolving the surfactant (egg lecithin) in the oil phase 
(soybean) and adding all to the aqueous phase. The pre-emulsion was then 
homogenized by a high-pressure homogenizer (110P series microfluidizer) 
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to obtain the final nano-emulsion (1). PLL-biotin solution was prepared by 
dissolving 10 mg in 1 ml Milli-Q water. The first positively charged layer of 
PLL-biotin was obtained by adding in one shot the polymer solution to the 
emulsion solution under vigorous stirring (1500 rpm) and then homogenized 
for 100 steps at a pressure of 700 bar by a high-pressure homogenizer (110P 
series microfluidizer). The secondary nanoemulsion solution was 0,0125 
wt% of PLL-biotin and 1 wt% of oil. The streptavidin (Sigma Aldrich) 
solution was prepared by dissolving 1 mg in 1 ml of Milli-Q water (166 
µM). The streptavidin solution was added to the O/W (0,5 wt%) PLL-biotin 
(0,00625 wt%) SNE under sonication at a final concentration 1,45 µM. In 
the same way the compound FITC-gH625-PEG-biotin was added under 
sonication to the PLL-biotin-streptavidin secondary nanoemulsion at a ratio 
1:1 between FITC-gH625-PEG-biotin and the streptavidin. The NCs were 
characterized at each step of preparation measuring size and ζ-potential by 
dynamic light scattering (Malvern Zetasizer). Before each experiment, 50 μl 
aliquots were withdrawn from each sample and diluted 1:40 (v/v) with 
Milli-Q water. The diluted samples were poured into disposable cells, and 
the size and ζ-potential was determined at least 3 times for each sample at 
25 °C. In particular, the particle size distribution was measured by DLS (λ= 
632.8 nm) using a detecting angle of 173°.  
The final nanoparticles were also characterized by confocal microscopy. A 
treatment of the WillCo dish was performed with a solution of poly-L-lysine 
(4-15 kDa): the solution 1mg/mL of poly-L-lysine was deposited for 10 min 
on the WillCo dish and then washed two times with Milli-Q water. The 
sample of NCs was diluted up to an oil concentration of 0.001 wt % using 
Milli-Q water and leaved in the dish for 30 min, then one part and half of 
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the diluted sample was substituted with a solution of 1,4-diazobiciclo-
(2.2.2)-benzeneoctane 5 wt % (in water). Confocal microscopy was 
performed by a confocal and multiphoton micro-scope system (Leica TCS 
SP5 MP, (Wetzlar). The lambda of the argon ion laser was set at 488 nm. 
Fluorescence emission was revealed by band pass 500–530. 1,4-
diazobiciclo-(2.2.2)-benzeneoctane and WillCo dishes were respectively 
from Sigma Aldrich and WillCo Wells B.V. 
 
 
 
3.2.4 Isothermal Titration Calorimetry Analysis 
 
Isothermal titration calorimetry (ITC) experiments were performed using a 
Nano ITC Low Volume from TA Instruments (USA) with a cell volume of 
170 μl. Titration experiments were carried out at 25 °C. 25 injections of 2 μl 
each of streptavidin solution (10,41 μM) were added to the PLL-biot NCs 
solution (0,00625% PLL-biot) every 200 s at a continuous stirring rate of 
200 rpm. Measurements were carried out to calculate the heat of dilution for 
streptavidin solution. Control experiments were performed between the 
streptavidin solution (10,41uM) and the PLL NCs solution (0,00625% 
PLL). The binding constant (Kb), enthalpy change (ΔbH°), and 
stoichiometry of the interaction process were obtained by fitting the binding 
isotherm to the equivalent and independent binding sites model, by using 
the NanoAnalyze software, version 2.4.1 (TA Instruments). The remaining 
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thermodynamic parameters of the interaction were calculated using the 
relationships: 
ΔbG° = −RTln Kb 
ΔbG° = ΔbH° − TΔbS° 
 
 
 
3.2.5 Permeability Experiments 
 
Cells were seeded at a density of 9 × 10
4
 cells/cm
2
 on transwell permeable 
inserts (6.5 mm in diameter, 3 μm pores size; Corning Incorporated, 
Corning, NY). Transendothelial electrical resistance (TEER) was measured 
by using Millicell1-ERS voltohmmeter (Millipore, Billerica, MA) to assess 
the growth of cells on inserts. Permeability experiments were performed on 
the monolayer 7 days after cell seeding, allowing sufficient time for the cells 
to develop the junctions between cells. On the day of experiment, transwell 
insert filter was washed with PBS, and then the media of the donor chamber 
was filled with 150 μl cell culture medium without phenol red and 
containing 4.3 × 10
8
 NPs/ml while the acceptor chamber was filled with 400 
μl cell culture medium without phenol red. The samples of 400 μl were 
drawn every 30 min for 240 min from the acceptor chamber and were then 
replaced with the same amount of fresh medium. The fluorescence tracer 
concentration in the samples was determined by a spectrofluorometer 
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(Victor, Wallac, PerkinElmer), and the excitation and emission wavelengths 
were set respectively to 488 nm and 530 nm. The cell nuclei were stained 
with 4′,6-diamidine-2′-phenylindole dihydrochloride (DAPI). Fluorescence 
analyses were performed by a confocal and multiphoton micro-scope system 
(Leica TCS SP5 MP). Images were acquired with a resolution of 1024 × 
1024 pixels by an oil-immersion 63× objective. 
 
 
 
3.3. Results and Discussion 
 
Oil in water primary and secondary poly-L-lysine nanoemulsions were 
previously reported and well characterized (21,22). In the latter case, it was 
utilized PLL modified with biotin (PLL-biotin), followed by the linker 
protein, streptavidin, and biotin end-functionalized PEGylated peptide 
(biotin-PEG-gH625-FITC). In Fig 3.2 it is shown a schematic illustration of 
the decorated NCs assembly. The first PLL-biotin layer is able to gain 
cellular entry of NCs indeed the mechanism of uptake for positively charged 
nanoparticles is energy driven due to the interaction with charged heparin 
sulfate on the cell surface that plays an important role for nanoparticles 
invagination (14). The streptavidin bridges PLL-biotin and biotin-PEG-
gH625 via streptavidin-biotin affinity interaction. Further, PEG has the role 
to enable the NCs to avoid clearance by mononuclear phagocytic system. It 
allows NCs to stay in the blood for extended period (23). Lastly, the 
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terminal peptide gH625 is able to traverse the membrane bilayer and 
transport the NCs into the cytoplasm and across the endothelium barriers. 
 
 
Figure 3.2 Schematic representation of PEG-gH625 decorated NCs 
formulation. 
 
As previously mentioned, the PLL was functionalized with biotin (Fig. 3.3) 
in order to create biotinylated NCs. The functionalization was detected by 
nuclear magnetic resonance (NMR). The peak at 3.0 ppm was assigned to 
the epsilon protons of free Lys (as confirmed by spectrum of PLL shown in 
Fig. 3.4 B) whereas peak at 2.9 ppm was assigned to the epsilon protons of 
Lys bound to biotin. The integration of those two peaks gives the percentage 
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of biotin bound to PLL in the PLL-biotin sample showing a yield of 
functionalization of 5%. This degree of polymer functionalization resulted a 
good compromise between the reduction of the polymer solubility induced 
by the biotin conjugation and the amount of new sites able to link PEG-
peptide necessary to improve cellular uptake. Further, PEG is able to 
explicate its anti-opsonic properties only if its density on nanoparticles 
surface is relatively low to allow the single chains to move freely. 
 
 
Figure 3.3 Scheme of poly-L-lysine functionalization with biotin. 
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Figure 3.4 1H1D NMR spectra of PLL-biotin (A) and PLL (B) in 90/10 
H2O/D2O. 
 
The O/W (1 wt%) PLL-biotin (0,0125 wt%) SNE was prepared and 
characterized by dynamic light scattering analysis which showed good 
results of size, polydispersity index and ζ-potential. The results 
demonstrated an increment of size from the primary nanoemulsion (137,3 
nm) to the PLL-biotin secondary nanoemulsion (154,3 nm) (Fig 3.5A). 
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Further, an inversion of nanoparticles charge was shown. Indeed, the ζ-
potential results negative in the primary nanoemulsion due to the presence 
of charged carboxylic acid groups along the lecithin chain (used as 
surfactant) and becomes positive in the secondary nanoemulsion due to the 
coating of the positively charged polymer (poly-L-lysine) (Fig. 3.5B). 
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Figure 3.5 Size data of O/W primary nanoemulsion compared with O/W (1 
wt%) PLL-biotin (0,0125 wt%) secondary nanoemulsion (A). ζ-Potential 
data of primary nanoemulsion compared with O/W (1 wt%) PLL-biotin 
(0,0125 wt%) secondary nanoemulsion (B). 
 
Overall, DLS periodicals measurements showed that the PLL-biotin 
secondary nanoemulsion maintains its hydrodynamic diameter until about 
49 days, thus demonstrating its good stability (Fig. 3.6). 
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Figure 3.6 Dimensional behaviour over time for O/W (1 wt%) PLL-biotin 
(0,0125 wt%) secondary nanoemulsion measured by DLS analysis. 
 
In order to establish the precise amount of streptavidin able to saturate all 
the biotin groups exposed on the surface of NCs, isothermal titration 
calorimetry experiments were carried out. The methodology is based on the 
measurement of the heat absorbed or released following titration by 
injecting a solution of one of the interacting molecules (the ligand) into a 
cell containing a solution of the other molecule (a macromolecule). In this 
case an O/W (0,5 wt%) PLL-biotin (0,00625 wt%) SNE was titrated with a 
solution of streptavidin (10,41 µM) (Fig. 3.7A). The ITC binding curve 
obtained from the integration of the heat data has a sigmoidal behaviour and 
was fitted with an independent and equivalent-sites model, the best-fit 
parameters are reported in Table 3.1. As shown in Table 3.1, the affinity 
between PLL-biotin NCs and streptavidin is very high, Kd (Kd=1⁄Kb ) values 
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are in the order of nM. The thermodynamic signature, traced by the 
thermodynamic parameters collected in Table 3.1 and depicted in Fig. 3.7B, 
clearly shows that the interaction is exothermic and enthalpically driven. 
The process is enthalpically driven counterbalanced by an unfavourable 
entropic contribution to Gibbs energy. The favourable enthalpy is ascribable 
to the formation of new interactions between biotin and streptavidin upon 
binding. The unfavourable entropy contribution upon binding, suggests that 
the unfavourable conformational rearrangements due to the loss of 
conformational degrees of freedom for both the interacting molecules, 
emerge predominant. To confirm that the obtained binding curve is only due 
to the interaction between the biotin and the streptavidin, the same 
experiment without biotin was carried out. In particular O/W (0,5 wt%) PLL 
(0,00625 wt%) SNE was titrated with a solution of streptavidin (10,41 µM). 
Raw data (Fig. 3.7C) showed only small peaks of dilution demonstrating no 
interaction between the streptavidin and O/W PLL SNE. 
 
Table 3.1 Thermodynamic parameters of the interaction between 
streptavidin and O/W (0,5 wt%) PLL-biotin (0,00625 wt%) SNE at 25 °C. 
molar 
enthalpy, 
∆H° 
(kJ mol
-1
) 
entropic 
contribution, 
T∆S° 
(kJ mol
-1
) 
Gibbs 
energy, 
∆G°(25 °C) 
(kJ mol
-1
) 
binding 
constant, 
Kb 
(M
-1
) 
-510,1 -463,24 -46,86 1,6*10
8 
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Figure 3.7 ITC data for titration by stepwise injections of streptavidin into 
0,5 wt% O/W PLL-biotin SNE at 25 °C (A). Normalized heat of interaction 
between PLL-biotin SNE and streptavidin. The solid circles are the 
experimental data obtained by integrating the raw data and subtracting the 
heat of ligand dilution into the buffer. The lines represent the best fit 
obtained with the independent-sites model (B). ITC data for titration by 
stepwise injections of streptavidin into 0,5 wt% O/W PLL SNE at 25 °C (C). 
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According to the NMR data the solution of O/W (0,5 wt%) PLL-biotin 
(0,00625 wt%) SNE is 14,5 µM concentrated in biotin (5% biotin on the 
total amount of PLL monomers used for the NCs formulation). Whereas 
ITC data show that the same NCs solution saturated by means of 
streptavidin is 1,45 µM concentrated in streptavidin. This means that 10% of 
biotins are exposed on the NCs surface and able to bind the streptavidin 
added to the solution. ITC experiments allowed to determine the exact 
amount of biotin exposed on the NCs surface with respect to the total 
quantity. These data were of fundamental importance to continue the 
decorated NCs assembly and avoid nonspecific interactions due to the 
addition of a larger amount of the biomolecules than the available sites. 
Regarding the peptide synthesis three glycines and a cysteine were added to 
the C-terminal (gH625-GGGC). The three glycines had a role of spacer in 
order to make the peptide free to acquire its conformation when conjugated. 
Whereas at the N-terminal a fluoresceine 5(6)-isothiocyanate (FITC) residue 
was added in order to dye the compound and detect its conjugation on the 
NCs (FITC-gH625-GGGC). The protector group was selectively removed 
from the thiol group of the last cysteine residue, still linked to the resin, then 
was conjugated to the maleimide group of a bifunctionalized 
polyethylenglycol (Mal-PEG-biotin, 2000 Da) obtaining the PEGylated 
peptide (FITC-gH625-PEG-biotin) (Fig. 3.8). PEG 2000 was chosen for its 
known capability to extend the circulation time and decrease accumulation 
in liver of nanoemulsion better than smaller or longer PEG (24). In literature 
it is reported that PEG2000-nanoemulsion has a 7-fold increased half-time 
after injection in rats (25). 
78 
 
 
Figure 3.8 Scheme of peptide synthesis on solid phase, PEGylation and 
washing. 
 
Analytical high pressure liquid chromatography and mass spectroscopy 
showed both the presence of the unreacted peptide and the PEGylated 
peptide with a yield of 37% (Fig. 3.9). The first main peak was associated to 
the peptide, the second to the PEGylated peptide. The two compounds were 
separated by RP-HPLC (reverse phase-high performance liquid 
chromatography). 
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Figure 3.9 RP-HPLC spectra at 220 nm of the reaction products. 
 
The secondary structures of gH625-GGGC and gH625-GGGC-PEG were 
determined in water by CD spectroscopy in the far-UV spectral region 
(195–260 nm). CD spectra performed on gH625-GGGC revealed spectra 
with minima at ∼200–205 nm, indicating the presence of a random coil 
conformation. This spectral characteristic is consistent with the CD spectra 
of gH625 reported in literature (26) demonstrating that the insertion of 
amino acids at the C-terminal does not disturb the peptide conformation. 
Further, the CD spectra performed on gH625-GGGC-PEG showed the same 
trend proving that the long PEG chain does not interfere with the peptide 
secondary structures (Fig. 3.10). 
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Figure 3.10 CD spectra of gH625-GGGC (black) and gH625-GGGC-PEG 
(red) in water. The spectra were recorded using 0.2 cm path length cells. 
 
The FITC-gH625-PEG-biotin was then added to the O/W PLL-biotin-
streptavidin SNE under sonication at a ratio 1:1 with the streptavidin. The 
completed functionalized NCs were characterized by DLS. The 
hydrodynamic diameter of these fluorescent nanoparticles was 156 nm, as 
illustrated by the typical light scattering measurement shown in Fig. 3.11A. 
Such systems were also evaluated by fluorescence confocal microscopy and, 
in order to improve NCs imaging resolution, stimulated emission depletion 
microscopy (STED) was also performed. Confocal imagine (Fig. 3.11 B) 
shows the good monodispersity of the colloidal system and absence of 
aggregates in accordance with DLS data. 
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Figure 3.11 Size data of PLL-biotin-streptavidin secondary nanoemulsion 
(black) and PLL-biotin-streptavidin-PEG-gH625 secondary nanoemulsion 
(red)(A). Confocal imagine of PLL-biotin-streptavidin-PEG-gH625 
secondary nanoemulsion. The scale bars is 2,5µm (B). 
 
In Table 3.2 size and ζ-potential measurements of NCs during each step of 
preparation are shown. As illustrated, an increment of size (from 137±0,56 
to 153,5±0,88) and a ζ-potential inversion (from -43,3±1,90 to 45,9±0,91) 
occurred in the passage from O/W NE to O/W SNE since the polymer forms 
a positively charged layer around the negatively charged oil droplets 
increasing their overall size. The next steps of conjugation did not change 
significantly the nanoparticle size in agreement with the fact that the 
functionalization degree is low and the conjugated compound is small with 
respect to the NC, in fact as reported in literature streptavidin hydrodynamic 
diameter is 7 nm (27). 
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Table 3.2 Size and ζ-potential measurements of NCs during the four steps of 
assembly. 
 Size PDI ζ-potential 
 
1.Primary 
nanoemulsion 
 
137,3±0,56 
 
0,041±0,003 
 
-43,3±1,90 
2.Secondary PLL-
biotin  
nanoemulsion 
 
153,5±0,88 
 
0,054±0,013 
 
45,9±0,91 
3.Secondary PLL-
biotin-streptavidin 
nanoemulsion 
 
153,8±0,56 
 
0,075±0,0063 
 
42,9±0,83 
4.Secondary PLL-
biotin-streptavidin-
PEG-gH 
nanoemulsion 
 
155,9±2,00 
 
0,099±0,01 
 
47,5±0,60 
4.Secondary PLL-
biotin-streptavidin-
PEG- negative 
control peptide 
nanoemulsion 
 
154,8±2,90 
 
0,068±0,02 
 
48,6±3,39 
 
To study the effect of the functionalization of gH625-PEG on O/W SNE 
(gH-NCs), transcytosis experiments were performed. In particular, to 
confirm the peptide capability to enhance NCs crossing of a confluent 
monolayer of endothelial cells, gH-NCs were compared  with NCs 
functionalized with a peptide that acts as negative control , whose sequence 
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was opportunely modified, through the substitution of amino acids 
considered fundamental for the interaction (named negative control peptide-
NCs). The negative control sequence (FITC-
BDGGAAAGAEEADAGAGGEAWGGGC) was synthetized on solid 
phase, PEGylated and conjugated on the nanocapsule surface in the same 
way practiced for gH625 peptide. bEnd3 cells are usually used as a BBB 
model system due to their rapid growth end capability to form a confluent 
monolayer that mimics the endothelium permeability (28-29). As shown in 
Fig. 3.12, after 60 minutes of incubation, both gH-NCs and negative control 
peptide-NCs crossed bEnd3 cells in the same amount. In both cases the 
number of internalized nanocapsules increases as a function of incubation 
time. However, the amount of crossing gH-NCs is higher than negative 
control peptide-NCs and this effect is more evident at longer incubation 
time. After 4 hours the bEnd confluent monolayer was washed and treated 
with a paraformaldehyde solution. Cells nuclei were DAPI stained and 
confocal microscope analyses were performed to confirm gH-NCs enhanced 
uptake (Fig. 3.13). Very interestingly, this analysis showed that despite the 
slight difference in terms of crossing gH-NCs accumulate much more than 
negative control peptide-NCs. 
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Figure 3.12 Transcytosis of gH-PEG-NCs (blue) and negative control 
peptide –PEG-NCs (red) in bEnd3 cells over 4hour. 
 
 
Figure 3.13 Confocal imagines for bEnd3 confluent monolayer after four 
hours in contact with gH-PEG-NCs (A) and negative control peptide PEG-
NCs (B) .The scale bars is 2,5µm. 
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A possible explanation is that the peptide induces much higher 
internalization. 
Very interestingly, due to the soft nature of the secondary nanoemulsions 
once internalized they tend to destabilize and remain in the cellular layer. 
This can be of particular importance when the release has to be localized in 
the layer of cells. 
Conversely, to enhance transcytosis properties of the above described 
nanocarrier one way, under investigation, is to reinforce NE system by 
thickening the shell through the layer by layer of further polymers.   
 
3.4 Conclusions 
 
In this work we synthetized and characterized O/W PEGylated SNEs 
decorated with gH-(625-644), a peptide that merges with biological 
membranes. The strong affinity interaction streptavidin-biotin was used for 
the PEGylation and the peptide conjugation. In vitro studies showed that 
gH625-644 enables the O/W NE both to cross and accumulate in the 
endothelial barriers. This propriety permits the NCs to be used in a double 
path. One as pharmaceutical form that accumulates in the vessel 
endothelium barrier, and in a sustained way releases its lipophilic cargo in 
the layer of cells making possible therapy of the endothelium layer or drug 
release from the layer to the tissue. The other as drug delivery system able 
to cross endothelium barriers; in this case we want to enhance the 
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transcytosis by reinforcing the shell through the layer by layer of further 
polymers.  
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CHAPTER 4   Energetics of Ligand-Receptor 
Binding Affinity on Endothelial Cells: an In Vitro 
Model 
 
 
4.1. Introduction 
 
Biological signaling plays a key role in cellular uptake of molecules by 
receptor mediated transport (RMT) (1). This mechanism is still not well 
understood, but binding of a specific ligand to its corresponding receptor is 
believed to induce an endocytic event that triggers the formation of 
endocytic vesicles (2). This mechanism is widely used to promote drug 
passage through cells or a layer of cells such as the blood brain barrier 
(BBB), which is a specialized vasculature and it is considered as the main 
barrier in preventing molecules from reaching the brain parenchyma (3-5). 
In the latter case the strategy consists in conjugating the drug or the system 
of the drug carrier with a molecule that recognize the overexpressed 
receptor on the BBB (6-9). As a consequence of the binding of the specific 
ligand to its corresponding receptor, endocytosis takes place via membrane 
invagination and the formation of an intracellular vesicle, which contains 
receptor-ligand complexes, occurs. Then, the vesicle is shuttled to the 
basolateral membrane (brain-side) releasing the vesicle content into the 
brain parenchyma (10). Thus, a detailed characterization of the cell 
membranes is of fundamental importance in order to identify the 
overexpressed receptors in each district and design the drug targeting to the 
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desired site. In particular, many studies show that, in the BBB, receptors of 
folate (11), insulin (12), low-density lipoprotein (LDL) (13), lactoferrin 
(14), and transferrin (Tf) (15) are overexpressed (16). Up to now, several 
studies, based on the conventional analytical methods mainly involving the 
fluorescence (i.e. immunofluorescence microscopy, flow cytometry and 
immunohistochemistry), aimed to the receptor quantification (17). 
Nevertheless, it is widely known that fluorescence spectroscopy is a non-
quantitative technique, strongly influenced by the surrounding environment. 
Thus, most of the developed assays provide only a relative assessment of 
protein level, rather than absolute quantification. In addition, imaging 
differences in receptor expression are often not very accurate because 
background fluorescence reduces precision of fluorescence intensity 
measurements (18). Recently, a quantification method for the determination 
of receptors levels, based on liquid chromatography–tandem mass 
spectrometry (LC–MS/MS), had been developed. This method requires a 
long and elaborate process (19), in particular, it requires membrane protein 
extraction, protein triptic digestion, choice of a stable isotope-labeled 
peptide as internal standard and finally a mass spectroscopy quantification 
that needs a highly selective detector.  
Herein, we propose for the first time a rapid, simple and quantitative 
methodology based on Isothermal Titration Calorimetry (ITC) coupled with 
confluent cell layers cultured around biocompatible templating 
microparticles to evaluate the number of transferrin receptors (TfRs) onto 
the cell membrane and study the energetics of their interaction with the 
transferrin. Thus far, ITC has been specially used to study interactions 
between molecules of biological interest (i.e. proteins-proteins, nucleic 
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acids-proteins, small molecules-nucleic acids) and in the last years it has 
been successfully applied to nanosystems (20-23). 
 
 
 
4.2. Materials and Methods 
 
4.2.1 Cell Culture 
 
Immortalized mouse cerebral endothelial cells, (bEnd3; American Type 
Culture Collection, Manassas, VA) were maintained in Dulbecco′s Modified 
Eagle′s Medium (DMEM) with 4.5 g/l w/o phenol red (Gibco-Thermo 
Fisher Scientific), supplemented with 10 % fetal bovine serum (FBS), 3.7 
g/l sodium bicarbonate and 4 mM glutamine, 100U/ml penicillin and 0.1 
mg/mL streptomycin, 1% non-essential aminoacids. bEnd3 cells used in all 
experiments from passage 21 to 30. Primary human umbilical vein 
endothelial cells (HUVECs; Lonza), used from passage 3 to 8, were cultured 
in Medium-200 (Cascade Biologics) supplemented with low serum growth 
supplement kit (LSGS kit) both purchased from Life Technologies of 
Thermo Fisher Scientific. Cells were grown at 37 °C and 5 % CO2. 
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4.2.2 Immunofluorescence Analysis 
 
Transferrin receptor (TfR) expression on cell membrane was evaluated by 
indirect immunofluorescence. Briefly, cells seeded on 12 mm diameter glass 
coverslips were fixed with 4 % paraformaldehyde at room temperature (RT) 
and incubated overnight at 4 °C with anti-transferrin receptor polyclonal 
primary antibodies (Invitrogen) diluted 1:1000 in blocking buffer (0.5 % 
bovine serum albumin (BSA) in PBS). Then, cells were incubated 1 h, at RT 
with anti-rabbit secondary antibodies Alexa-488 (Invitrogen) diluted 1:1000 
in the blocking buffer. Cell nuclei were stained with 4',6-diamidino-2-
phenylindole blue nuclear dye (DAPI) purchased from Sigma. Samples 
were mounted on a glass slide and observed by confocal microscope (MP 
Leica TCS SP5) equipped with a 63 × oil immersion objective. 
 
 
 
4.2.3 Cell Seeding on Cytodex Microspheres 
 
Pyrex glass vial was coated with Sigmacote (Sigma) for 5 min before use to 
prevent cell adhesion on the walls. Dextran microcarrier beads (Cytodex® 3 
purchesed from Sigma) were weighed in the vial and swelled with PBS for 3 
h, at RT under gentle stirring. Afterwards the vial was autoclaved to prevent 
contamination. After sterilization, Cytodex suspension was decanted and 
PBS was removed to resuspend the beads at a concentration of 5 mg/ml in 
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cell culture medium. 2 ml of Cytodex suspension were transferred into each 
well of a low attachment 6-well plate (Corning). 8 × 105 cells in 100 µl of 
cell culture medium were added to the Cytodex in the well. In order to allow 
cell adhesion to the surface of the microspheres, the 6-well plate was kept 
under stirring at 80 rpm overnight in incubator at 37 °C and 5 % CO2. 
Stirring was stopped for 1 min every 15 min for the first 3 h from the 
seeding. After overnight incubation, 7 ml of Cytodex with adhered cells 
were collected and cells were fixed with 4 % paraformaldehyde for 10 min 
before ITC analysis. Cell adhesion on Cytodex was monitored by phase 
contrast microscopy. After cell seeding procedure, cell suspension was 
analyzed by Neubauer chamber to verify that all the seeded cells were 
adhered to the microspheres. Moreover, in order to further verify cell 
adhesion on the Cytodex microspheres, after fixation, cells were stained 
with Phalloidin–Tetramethylrhodamine B isothiocyanate (Phalloidin-
TRITC) by Invitrogen to detect actin filaments and with DAPI to detect 
nuclei. Samples were observed by confocal microscope with a 10 × 
objective. 
 
 
 
4.2.4 Sample Preparation 
 
Holo-Transferrin was purchased from Sigma Aldrich, the solution was 
prepared by dissolving the lyophilized compound in a fresh PBS buffer 
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solution pH = 7.4 every time before each ITC measurement. The 
concentration of Tf solution was determined by UV adsorption 
measurements at 295 K using sequence based molar extinction coefficient 
values (280nm) of 85240 M
-1
cm
-1
. bEnd3 or HUVEC cells cultured on 
Cytodex microbeads solutions were suspended in PBS buffer solution pH = 
7.4, as these systems tend to settle as sediment after few minutes, all the 
solutions were maintained under soft stirring conditions until the loading in 
the ITC cell in order to ensure homogeneity of the samples. 
 
 
 
4.2.5 Isothermal Titration Calorimetry  
 
ITC experiments were performed using a Nano ITC Low Volume from TA 
Instruments (Lindon, UT, USA) with a cell volume of 170 μl. All solutions 
were accurately degassed before the ITC experiments to avoid the formation 
of air bubbles in the calorimeter cell. The sample cell was loaded with 
bEnd3 or HUVEC cells cultured on Cytodex microbeads in PBS buffer 
solution, Tf instead was loaded into the computer-controlled microsyringe 
in the same buffer conditions. Injections were started after baseline stability 
had been achieved. Titration experiments were carried out at 298 K, 10 
injections of 5 μl of Tf 1- 0.1 µM were added to the bEnd3 or HUVEC cells 
cultured on Cytodex microbeads (1800000 - 5600000 cells/mL) every 250 s. 
Control experiments were carried out to calculate the heat of dilution for Tf 
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in PBS solution. All the measurements were conducted at a continuous 
stirring rate of 250 rpm.  
Raw data were obtained as a plot of heat released against time and featured 
as a series of peaks for each injection. The calorimetric enthalpy for each 
injection was calculated after correction for the heat of Tf dilution, the area 
under raw data peaks was integrated by the analysis software of the 
instrument (NanoAnalyze software, version 2.4.1 (TA Instruments)) to 
obtain a plot of enthalpy change per mole of injectant (Tf) against the 
number of TfRs per cell. From the number of cells/ml was calculated the 
number of cells for each experiment. The number of TfRs was calculated 
taking into account the moles of added Tf, until the saturation occurs, this 
value correspond to half of the TfRs present in the sample cell. Holo -
transferrin was previously shown to bind to the receptor with a 
stoichiometry of one Tf molecule per TfR monomer (stoichiometry Tf-TfR 
2:1) (24). Each experiment was repeated up to three-five times in order to 
ensure reproducibility. Integrated heat data obtained for the titrations were 
ﬁtted using a nonlinear least-squares minimization algorithm to a theoretical 
titration curve, using NanoAnalyze software, version 2.4.1 (TA 
Instruments). ∆bH° (reaction enthalpy change in kJ mol
-1
), Kb (binding 
constant in M
-1
), and n (number of binding sites) were the ﬁtting parameters 
obtained by the equivalent and independent binding sites model. 
The remaining thermodynamic parameters of the interaction were calculated 
using the following equations:  
ΔbG° = −RT ln Kb, (R = 8.314 J mol
−1
 K
−1
, and T = 298 K)  
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TΔbS° = ΔbH° − ΔbG° 
The values in the Table 4.1 show the determination of average and average 
deviation of ITC measurements. 
 
 
 
4.3. Results and Discussion 
 
4.3.1 Choice of Cells and Microparticles  
 
In this study, we use mouse brain endothelial cells (bEnd3) and primary 
human umbilical vein cells (HUVEC) cultured on dextran microbeads with 
size ranging from 67 µm to 80 µm (Cytodex) (25). The bEnd3 cells are 
usually used as a BBB model system due to their numerous advantages: 
rapid growth, formation of functional barriers, amenability to numerous 
molecular interventions and preservation of blood–brain barrier properties 
over repeated experiments (26-30).  
We chose to compare bEnd3 cell line and HUVEC cells because they have 
different expression levels of TfR. We firstly evaluated TfR expression 
levels on bEnd3 and HUVEC by indirect immunofluorescence microscopy. 
As reported in Fig. 4.1A, bEnd3 cells showed a brighter fluorescent signal 
than that of HUVECs (Fig. 4.1B). These observations indicate that the TfR 
expression level on the membrane surface of bEnd3 is higher than that of 
HUVEC cells. 
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Figure 4.1 TfR expression in bEnd3 (A) and HUVECs (B) evaluated by 
indirect immunofluorescence without cell permeabilization. Images were 
acquired by confocal miscroscope with 63 × oil immersion objective. Green 
fluorescence represents TfR proteins, blue fluorescence indicates cell nuclei 
stained with DAPI. 
 
4.3.2 Optimization of Cell Seeding on Cytodex Microspheres 
 
Starting from these preliminary results, we optimized the procedure of cell 
seeding on Cytodex microspheres. Cytodex system allows having a higher 
number of cells in a small volume maintaining the correct morphology of 
adherent cells compared to cell suspensions obtained upon trypsin 
treatment. In the latter case, in fact, cells become round in shape thus losing 
their canonical phenotype of adherent cells. Transmitted light microscope 
images show Cytodex beads with a smooth surface (Fig. 4.2A). After cell 
seeding, the surface of Cytodex beads appears rough compared to original 
beads indicating the presence of the cells on it (Fig. 4.2B). 
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Figure 4.2 Phase contrast microscopy micrographs of Cytodex microsphere 
suspension before (A) and after (B) cell seeding. 
Moreover, confocal microscopy images further confirm the presence of a 
confluent layer of cells on the Cytodex surface (Fig. 4.3). In particular, 
phalloidin staining of the actin cytoskeleton demonstrates the correct 
spreading of the cells (Fig. 4.3). 
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Figure 4.3 Maximum projection of z-sectioning images obtained by 
confocal microscopy with 10 × objective of a Cytodex microsphere after 
bEnd3 cell seeding (A-D). Actin microfilaments are stained in red by 
Phalloidin-TRITC (A), cell nuclei are represented in blue by DAPI (B) and 
the Cytodex is acquired in transmitted light (B). Merge of the three channels 
is reported in D. 
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4.3.3 Isothermal Titration Calorimetry Experiments 
 
ITC experiments allowed us to monitor the binding between Tf and TfRs 
present on the cell membrane simply measuring the heat released upon 
molecular interactions (31). The binding curve provided the complete 
thermodynamic profile (i.e., binding constant (Kb), enthalpy change (∆H°), 
entropy change (∆S°), Gibbs energy change (∆G°)) of the interaction. 
Taking into account that two molecules of Tf bind to one molecule of TfR 
(32), the number of TfRs/cell was calculated considering the Tf moles 
necessary to saturate all the TfRs present in the sample and dividing for the 
number of loaded cells. The assessment of TfR number on cells by ITC, 
obtained from the specific interaction between Tf and TfR, is very important 
to overcome the problem of nonspecific interactions that could occur at 
higher Tf concentration. Indeed, most of conventional analytical methods 
are conducted adding an excess of Tf to the cell culture and then removing 
the unbinding molecules by washing (33, 34). This could provide an 
overestimation of receptor numbers, due to the nonspecific interactions, that 
is detrimental for an effective targeting action. The ITC experiments, 
performed by using bEnd3 and HUVEC cells cultured on Cytodex 
microbeads are shown in Fig. 4.4 and Fig. 4.5. 
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Figure 4.4 ITC raw data for titration of Tf solution (1µM) into the solution 
of bEnd3 cells (1800000 cells/mL) cultured on Cytodex microbeads (a). The 
solid circles are the experimental data obtained by integrating the raw data 
and subtracting the heat of Tf dilution into the buffer. The solid line 
represents the best fit obtained with the independent-binding site model (b). 
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Figure 4.5 ITC raw data for titration of Tf solution (0.1µM) into the 
solution of HUVEC cells (5600000 cells/mL) cultured on Cytodex 
microbeads (A). The solid circles are the experimental data obtained by 
integrating the raw data and subtracting the heat of Tf dilution into the 
buffer. The solid line represents the best fit obtained with the independent 
binding site model (B). 
 
ITC results showed that the binding reaction between Tf and TfRs on bEnd3 
and HUVEC cells was exothermic and accomplished by an unfavorable 
entropy, indicating that the interaction is enthalpically driven (Table 4.1).  
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Table 4.1. Thermodynamic parameters of the interaction between Tf protein 
and TfR on bEnd3 and HUVEC cells cultured on Cytodex microbeads. 
 n 
a) 
Kd 
[nM] 
b) 
ΔH° 
[kJ mol
-1
]
 c)
 
TΔS° 
[kJ mol
-1
]
 c)
 
ΔG°(298 K) 
[kJ mol
-1
]
 b)
 
bEnd3 
 
2.7 10
7
 3.7 -794 -746 -48 
HUVEC 4.5 10
5
 4.4 -575 -528 -47 
a) n refers to the number of TfRs per cell; b) The experimental error for Kd 
and Gibbs energy is <20%; c) The experimental error for enthalpy and 
entropy change is < 25%. 
 
 
Figure 4.6 Schematic diagram presenting the thermodynamic signature for 
the Tf- TfR binding on bEnd3 cells cultured on Cytodex microbeads (A) and 
Tf- TfR binding on HUVEC cells cultured on Cytodex microbeads (B). 
 
 
ITC experiments were also performed titrating the Tf solution into the 
solution of Cytodex microbeads without cells. With each injection of ligand, 
constant heat release was observed due only to Tf dilution, proving that it is 
no longer able to interact with microbeads without cell. An example of the 
raw ITC data is shown in Fig. 4.7. 
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Figure 4.7 ITC raw data for the titration of Tf solution (1µM) into the 
solution of Cytodex microbeads  (35 mg in 1.5 mL) into PBS buffer solution. 
 
ITC experiments of Tf injected into free bEnd3 cells in solution without 
Cytodex microbeads showed irresolvable binding isotherm, with scattered 
points, which do not allow to evaluate the thermodynamic parameters (Fig. 
4.8). These findings confirm the validity of the experiments conducted using 
bEnd3 and HUVEC cells cultured on Cytodex microbeads. 
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Figure 4.8 ITC raw data for the titration of Tf solution (1µM) into the 
solution of 1800000 cells/ml bEnd3 cells without Cytodex microbeads (A). 
The solid squares are the experimental data obtained by integrating the raw 
data and subtracting the heat of Tf dilution into the PBS buffer solution (B). 
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4.3.4 Energetics of Tf-TfRs Binding on Cells 
 
The energetics of interactions is context-dependent, for this reason thanks to 
the use of Cytodex, we studied the binding in near-physiological conditions, 
where the TfRs are in their natural location, which is the membrane of cells 
residing in a continuous and confluent layer.  
As shown in Table 4.1, the affinity between Tf and TfRs in both systems is 
very high, Kd (Kd=1⁄Kb) values are in the order of nM. Conversely, the value 
of TfRs/cell reveals a 100-fold increase in the number of TfRs per bEnd3 
cells compared to HUVEC cells. The values in Table 4.1 show the number 
of receptors/cell that, divided by the Avogadro number, gives 45 
attomol/cells and 0.74 attomol/cells for bEnd3 and HUVEC cells, 
respectively. These values are comparable with those recently obtained for 
TfRs on other kinds of cells, assessing the validity of our method which 
conversely is much more simple than the proposed quantification method 
based on LC-MS/MS (19). In addition, the number of receptors has never 
been calculated for a continuous layer of cells such as a BBB mimicking 
model system. Analogously, due to the lack of a realistic model, previous 
ITC studies even showing similar affinity (Kd~ 1nM) for the Tf-TfR 
interaction with just the proteins in solution provided both enthalpically and 
entropically driven binding, in contradiction with our findings (24). Indeed, 
the thermodynamic signature of the binding, i.e. the proportion by which the 
enthalpy and entropy contribute to the Gibbs energy, illustrated in Fig. 4.6, 
clearly shows that the binding is enthalpically driven for our systems. The 
measured enthalpy changes are the result of the formation and breakage of 
many interactions: protein–water and ligand-water hydrogen bonds, van der 
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Waals interactions, water network reorganisation near the protein surface, 
direct ligand-protein bonds, such as salt bridges, hydrogen bonds and van 
der Waals contacts, and many others. Each of these sub-contributions is 
attributable to non-covalent interaction contribute to measured enthalpy 
change, but it is not possible quantify each of them. Nevertheless, we can 
assume that the establishment of new interactions between interacting 
proteins and water network reinforcement near complex surface (favorable 
enthalpy) overcome the breaking of many other interactions, among these 
the loss of water molecules from a binding pocket (unfavorable enthalpy). 
However, for both the systems, the favorable enthalpic contribution is 
partially counterbalanced by the unfavorable entropic contribution to Gibbs 
energy. Consequently, the Gibbs energy is around values of a few tens of 
kJmol
-1
. The cause lies in the thermodynamic behaviour, known as 
enthalpy-entropy compensation, and it is common to many receptor–ligand 
complexes, whose ITC thermodynamic data have been collected by Li et al. 
(35). Actually, the observed enthalpy-entropy compensation lies in the 
different structural properties of water molecules surrounding the interacting 
partners (36). The water contribution, indeed, is important as well as the 
direct interactions between the receptor and the ligand in shaping the 
thermodynamic signature of molecular interactions. Particularly, for binding 
entropy, it is known that two main contrasting terms are important, the 
favorable release of water due to the desolvation of the interacting groups of 
the proteins and unfavorable conformational rearrangements due to the loss 
of conformational degrees of freedom for both the interacting proteins upon 
binding. As our findings, show an unfavorable entropy contribution upon 
binding, they suggest that the latter contribution described emerges 
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predominant when TfRs are on the cells in contrast to a favorable entropic 
contribution for free proteins in solution mainly ascribable to the release of 
water. Finally, our thermodynamic data that relate to a more realistic model 
represents a suitable tool for drug design, suggesting to move toward an 
improvement of the conformational freedom of a potential drug upon 
binding, for example introducing proper structural modifications to partially 
overcome the penalty in entropy (37). 
 
 
 
4.4. Conclusions 
 
In conclusion, our methodology provides a significant advance in the cell 
membrane receptor quantification. To the best of our knowledge, there has 
been no previous study on the energetics of interaction between a receptor 
on the cell membrane and its ligand. In this study, a simple assay based on 
Isothermal Titration Calorimetry coupled with cell layers cultured around 
biocompatible templating microparticles has been developed to determine 
TfR expression in two different kind of endothelial cells. Adhesion of cells 
on dextran microbeads allow them to adopt their canonical phenotype of 
adherent cells. The new methodology gives a more accurate quantification 
of proteins than the conventional analytical methods and possesses several 
advantages. It does not utilize complex and expensive detection systems. It 
does not require specific labeling of the target protein with specific 
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fluorophores, as for immunofluorescence microscopy, flow cytometry and 
immunohistochemistry. In addition, the fluorescent probes often possess 
limited photostability and scarce emission intensity (38). Even if 
photostable dyes have been recently utilized (39), they are very expensive. It 
does not require protein extraction, digestion and isotope-labeled peptide 
internal standard as for other methodologies like LC-MS/MS-based targeted 
proteomics assay (19).  
The methodology here proposed is based instead on a direct measurement of 
the number of receptors on the cells together with a detailed analysis of the 
energetics of interaction, providing complete information on receptor 
overexpression in a near-physiological conditions. These ﬁndings pave the 
way for an optimal design of new active drugs targeting towards specific 
tissues and shed new insights into the emerging ﬁeld of nanotechnology. 
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CHAPTER 5   Preliminary Characterization of 
O/W Nanoemulsions Electrostatically 
Bioconjugated 
 
 
5.1 Introduction 
 
Nowadays, cancer is one of the leading causes of death, in particular 
American Cancer Society estimates that one in 4 deaths in the United States 
is due to cancer (1). As already said, nanocarriers (NCs) for the delivery of 
drugs are attracting increasing research interest due to their capability to 
carry a wide range of compounds and to release them in the ill cells/organs 
(2-5). We extensively discussed about the fact that accumulation of NCs in 
the ill tissue is due to a spontaneous phenomenon called passive targeting or 
“Enhanced Permeability and Retention” (EPR) coming from a damaging of 
the vessel walls surrounding an inflamed or tumor region (6-9). However, in 
the case of blood brain vessels they tend to keep their impermeable feature 
even in the presence of a tumor (10). Recently great attention has been 
forwarded to the nineteen residues peptide gH625, a membrane-perturbing 
domain in the glycoprotein gH of Herpes simplex virus type I (11-15). In 
particular, it was verified that gH625 conjugation enhances nanoparticles 
transport across the BBB, thereby enhancing the central nervous system 
(CNS) bioavailability of a possible drug (16).  
Nowadays the scientific community is making great efforts to improve 
cancer management trying to simplify as much as possible the preparation 
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procedure of the nanocarriers. To this aim, since in vitro studies conducted 
on gH625 decorated O/W NCs showed good results (chapter 3), herein an 
easy electrostatic strategy has been proposed to bind gH625 on the external 
surface of polymeric nanocapsules prepared via layer by layer using an O/W 
nanoemulsion as template (17).  
The peptide was synthetized in a novel way with a tail of six charged amino 
acids which confers the peptide electrostatic proprieties and so the 
possibility to be bound using the layer by layer’s main principle. Peptide 
deposition was followed by analyzing surface charge through ζ-potential 
measurements in combination with ITC analysis as a fine method which 
also provides thermodynamic information on the peptide coating. 
5.2 Materials and Methods 
 
5.2.1 Nanocapsules Preparation 
 
First, a 20 wt % oil in water pre-emulsion (130-140 nm, ∼−30 mV, pH 4.3) 
was prepared by dissolving the surfactant (egg lecithin) in the oil phase 
(soybean) and adding all to the aqueous phase. The pre-emulsion was then 
homogenized by a high-pressure homogenizer (110P series microfluidizer) 
to obtain the final nano-emulsion (18). The first positively charged layer of 
poly-L-lysine-FITC (PLL-FITC) was obtained by adding in one shot the 
polymer solution to the emulsion solution under vigorous stirring (1500 
rpm). The SNE was 0,0125 wt% of PLL and 1 wt% of oil. The right amount 
of polymer coating was previously discussed (19). The second negatively 
charged layer (heparin) was obtained in the same way by adding the 
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negatively charged polymer, heparin, to the positively charged SNE; final 
heparin concentration was 0,009375 wt%. At the same way the PLL-FITC 
third layer was obtained by adding the polymer solution into the bilayer 
nanocapsules solution, it was 0,02812% of PLL-FITC. Whereas the bilayer 
constituted by hyaluronic acid (HA) on PLL was obtained by adding a 
solution of HA to the PLL SNE under stirring; in the final preparation HA 
was 0,0156 wt%. Poly-L-lysine (PLL, 4−19 kDa) and heparin sodium salt 
from porcine intestinal mucosa (Hep, 18000 kDa) were purchased from 
Sigma-Aldrich. 
The polymeric nanocapsules were characterized measuring size and ζ-
potential by dynamic light scattering (Malvern Zetasizer). In the ζ-potential 
measurement a voltage gradient is applied across a pair of electrodes of the 
cell containing the particle dispersion. Charged particles are attracted to the 
oppositely charged electrode, and their velocity can be measured and 
expressed in unit field strength as an electrophoretic mobility. ζ-potential 
measures were conducted in the same way described in chapter 3. The 
diluted samples were poured into disposable cells, and the ζ-potential was 
determined at least 3 times for each sample at 25 °C. Size measurements 
were also performed by a Malvern Zetasizer. In particular, the particle size 
distribution was measured by laser DLS (λ= 632.8 nm). This technique 
correlates the fluctuations of scattered light intensity I(t) during time with 
the Brownian motion of colloidal particles associated with the diffusion 
coefficient D, which is related to the hydrodynamic radius Rh of the 
particles. A detecting angle of 173° was used. All samples were diluted up 
to a droplet concentration of approximately 0.025 wt % using Milli-Q water. 
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5.2.2 Peptide Synthesis 
 
gH625 peptide was synthesized in a modified version, with a spacer of three 
glycines and a tail of six lysines at the C-terminal (gH625(6K)) in the first 
case. In the second case it was added a tail of six glutamic acids 
(gH625(6E)). It was employed the solid-phase method and standard Fmoc 
strategies. Rink-amide resin (substitution 0.48 mmol/g) was used as solid 
support. Activation of amino acids was achieved using 2-(1H-
Benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate: 
hydroxybenzotriazole: N,N-diisopropylethylamine (HBTU/HOBt/DIEA) (1 
: 1 : 2). All couplings were performed for 15 min and deprotections for 10 
min. All the synthesis were conducted under Mw treatment. Peptides were 
removed from the resin, after acetylation step, by treatment with a 
TFA/TIS/H2O (90 : 5 : 5, v/v/v) mixture for 90 min at room temperature, 
then, crude peptide was precipitated in cold ether, dissolved in a 
water/acetonitrile (1:1, v/v) mixture, and lyophilized. Products were purified 
by RP-HPLC applying a linear gradient of 0.1% TFA in CH3CN/ 0.1% 
TFA in water from 15% to 75% over 25 min using a semipreparative 10 x 
100 mm C18 column at flow rate of 5 mL/min. Peptides purity and identity 
were confirmed by LC-MS (Agilent 6530 Accurate-Mass Q-TOF LC/MS 
spectrometer). Purified peptide was lyophilized and stored at 4 °C until use. 
Reagents for peptide synthesis (Fmoc-protected amino acids, resins, 
activation, and deprotection reagents) were from Iris Biotech GMBH. 
Solvents for peptide synthesis and HPLC analyses were from Sigma 
Aldrich; reversed phase columns for peptide analysis were supplied from 
Waters. Solid phase peptide synthesis was performed on a fully automated 
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multichannel peptide synthesizer Biotage. Preparative RP-HPLC was 
carried out on a Waters 600 Controlled, equipped with a Waters 2489 
UV/Visible detector and with a Waters C18 column (10 x 100 mm, 5 µm).  
 
 
 
5.2.3 Isothermal Titration Calorimetry Analysis 
 
Isothermal titration calorimetry (ITC) experiments were performed using a 
Nano ITC Low Volume from TA Instruments (Lindon, UT, USA) with a 
cell volume of 170 μl. Titration experiments were carried out at 25 °C. Two 
set of experiments were performed: in the first experiment 10 injections of 5 
μl each of gH625(6K) solution (145,7 μM) were added to the nanocapsules 
solution (5,2 μM of heparin, 0,5% oil) every 250 s at a continuous stirring 
rate of 250 rpm, in the second experiment 10 injections of 5 μl each of 
gH625(6K) solution (3084 μM) were added to the nanocapsules solution 
(5,2 μM of Heparin, 0,5% oil) in order to test higher ratios .Control 
experiments were carried out to calculate the heat of dilution for 
gH625(6K). The binding constant (Kb), enthalpy change (ΔbH°), and 
stoichiometry of the interaction process were obtained by fitting the binding 
isotherm to the equivalent and independent binding sites model, by using 
the NanoAnalyze software, version 2.4.1 (TA Instruments). The remaining 
thermodynamic parameters of the interaction were calculated using the 
relationships: 
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ΔbG° = −RTln Kb 
ΔbG° = ΔbH° − TΔbS° 
where ΔbG° is the binding free-energy change, ΔbH° is the binding enthalpy 
change, ΔbS° is the binding entropy change, R is the gas constant (R = 
8.314 J mol
−1
 K
−1
), and T is the temperature in Kelvin (T = 298 K). 
 
 
 
5.2.4 Circular Dicroism Analysis 
 
Circular dichroism (CD) spectra were recorded on a Jasco 1500 circular 
dichroism spectrophotometer (Easton, US) in a 0,2 cm path length cuvette 
and the wavelength was varied from 260 to 190 nm. The spectra were 
recorded with a response of 4 s at 2.0 nm bandwidth and normalized by 
subtraction of the background scan with buffer for peptide in solution 
spectra and with nanocapsules solution for peptide on nanocapsules spectra. 
The oligonucleotide concentration was 9,8 μM. 
 
 
 
 
126 
 
5.2.5 Confocal Microscopy 
 
For the confocal microscopy a treatment of the willCo dish was performed 
with a solution of Poly-L-lysine (4-15 kDa) 1mg/ml for ten minutes and 
then washed two times with Milli-Q water. The sample was diluted up to an 
oil concentration of 0.001 wt % using Milli-Q water and leaved in the dish 
for 30 minutes, then one part and half of the diluted sample was substituted 
with a solution of 1,4-diazobiciclo-(2.2.2)-benzeneoctane 5 wt % (in water). 
Confocal microscopy was performed with a confocal laser-scanner 
microscope SP5 Leica. The lambda of the argon ion laser was set at 488 nm. 
Fluorescence emission was revealed by band pass 500–530. 1,4-
diazobiciclo-(2.2.2)-benzeneoctane and WillCo dishes were respectively 
from Sigma Aldrich and WillCo Wells B.V. 
 
 
 
5.3 Results and Discussion 
 
The polymeric bilayer nanocapsules (Hep/PLL) on oil core were prepared at 
the saturation polymer concentration for each layer and characterized by 
confocal microscopy (Fig. 5.1) and DLS (Fig. 5.2). Confocal imagine 
showed a good monodispersity of the colloidal system and absence of 
aggregate in accordance with DLS data which showed an hydrodynamic 
diameter of 144,3 nm, a polydispersity index of 0,071, and a ζ –potential of 
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-44,4 mV for the bilayer (Hep/PLL) NCs. In particular, in Fig. 5.2 they are 
shown hydrodynamic diameter and ζ-potential data of the nanocapsules 
during the three steps of preparation: O/W NE, poly-L-lysine-FITC 
monolayer, Hep/PLL bilayer. An increase of almost 10 nm in the size was 
observed coating the O/W NE with the first layer of polymer (poly-L-
lysine), whereas no increase in the diameter was observed coating with the 
second layer of polymer (heparin), probably due to a better compaction of 
the polymeric chains on the oil droplets. 
 
Figure 5.1 Confocal microscope images of nanocapsules with a double 
layer of polymer (heparine on poly-L-lysine) on oil core. Scale bar is 2,5 
µm. 
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Figure 5.2 Size (A) and ζ –potential (B) data of O/W NE in black (Size:134 
nm, PDI:0,034,  ζ –potential: -37,3 mV) monolayer of PLL in red (Size: 
146,7 nm, PDI: 0,063, ζ –potential:38,8 mV) and the bilayer of heparin in 
blue (Size:144,3, PDI: 0,071, ζ –potential -44,4mV). 
 
The peptide gH625 was synthetized in a modified version with six residues 
of lysines at the C-terminal (gH625(6K)) which are positively charged at the 
pH of the polymeric bilayer nanocapsules solution (pH=7) and able to bind 
the negatively charged surface of heparin through electrostatic interaction 
exploiting the main principle of layer by layer methodology (Fig. 5.3). 
Further, a spacer of three glycines was added between the tail and the 
peptide in order to confer the peptide the possibility to acquire its 
conformation. In Fig. 5.4 is shown the UV spectrum followed at 220 nm of 
the Analytical RP-HPLC of the purified peptide. 
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Figure 5.3 Strategy of synthesis of gH625(6K) on solid phase. 
 
 
Figure 5.4 UV profile (220 nm) of the RP-HPLC of the pure peptide 
gH625(6K). 
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In the described conditions only the lysine’s tail of the peptide is fixed on 
the nanocapsules, whereas the functional part is free to assume its 
conformation and explicate its action when in contact with cell membrane’s 
phospholipids. CD spectra showed an unchanged conformation of the 
peptide when on the nanoparticles (Fig. 5.5), proving that only the peptide’s 
electrostatic tail interacts with the nanoparticles, the rest of the peptide 
remains in solution free to assume its conformation. 
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Figure 5.5 CD spectra of the peptide in solution (red) and the peptide 
attached to the nanocapsules (black). 
 
To better explore the peptide deposition at different concentrations, it was 
performed a ζ-potential curve in relation to the ratio (w/w) between the 
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peptide and the outermost polymer layer. The ζ-potential of the bilayer 
nanocapsules was negative in absence of peptide which is due to the 
presence of carboxylic acid groups on the chains of the outermost layer of 
heparin. When the peptide concentration was increased, the ζ-potential 
initially became increasingly less negative, with a point of zero charge at 
around R=1,34, and reached a plateau for higher concentrations at R=16 
(Fig. 5.7A). The functionalized nanocapsules resulted to have good values 
of size and PDI at the concentrations of peptide that gave the nanoparticles a 
charge minor of -6 (R<0,9) and major of +6 (R>2). Isothermal titration 
calorimetry analysis allowed to monitor the interaction between the 
negatively charged nanoparticles and the peptide’s positively charged tail 
from a thermodynamic point of view. In order to test a wide range of 
concentrations of the peptide interacting with the nanoparticles two 
experiments were designed. In the first experiment ratios (peptide/heparin % 
w/w) from 0,149 to 1,49 were tested (Fig. 5.6) whereas, in the second 
experiment ratios were from 3 to 30 (Fig. 5.7B). In both cases low raw heat 
rate (µJ/sec) were registered at each injection proving that nonspecific 
electrostatic interactions are occurring. In the first experiment they were 
observed a nonspecific interaction between the peptide and the nanocapsules 
from ratio 0,14 to 0,74 and anomalous peaks without a significant trend 
from ratio 0,89, showing a destabilization of the nanocapsules due to a 
charge too near to zero, as already seen from DLS (Fig. 5.7A). From the 
second experiment it was possible to observe the right R at which the 
nanoparticles are saturated by means of the peptide, these data were fitted 
by an “independent site model” (Fig. 5.7B). 
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Figure 5.6 ITC raw data for the titration of gH625 solution (145,7 μM) into 
the solution of Hep/PLL bilayer nanocapsules 0,5% oil. 
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Figure 5.7 ζ –potential curve of the functionalized nanoparticles in relation 
to the ratio between the peptide and the heparin (w/w)(A.) ITC data for 
titration by stepwise injection of gH625(6K) into nanocapsules solution 
0,009375% heparin and 0,5% oil at 25 °C. The solid squares are the 
experimental data obtained by integrating the raw data and subtracting the 
heat of gH625(6K) dilution into the buffer. The red lines represent the best 
fit obtained with the independent-site model (B). 
 
From the data of the second ITC experiment emerged that the binding event 
is exothermic (∆H°= -2,85 kJ*mol-1) and is accomplished by a favorable 
entropy (T∆S°=25,75 kJ*mol-1), indicating that it is entropically driven, 
probably because of the release of ordered water by the hydration shells 
around the positive and negative charges in disordered bulk water (20,21). 
In the complex the binding event between the peptide and the outermost 
polymer is a spontaneous phenomenon (∆G°= -28,60 kJ*mol-1). The low 
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binding constant (Kb=1,04*10
5
) is a demonstration that non-specific 
interactions like electrostatic are occurring.  
It appeared clearly that from R pep/Hep 0,14 to 0,89 the peptide interacts with 
the nanocapsules without altering their stability. Conversely, from ratio 0,89 
the amount of attached peptide was such to reduce the negative charge of 
the nanocapsules and cause destabilization. This destabilization stopped at 
ratio 2 where the nanocapsules charge became enough positive to confer 
them the right stability. 
In a first instance we conducted in vitro studies on the NCs of Hep/PLL 
(R=1,5), pep/Hep (R=0,4). Anyway, these studies did not show a difference 
of cellular uptake from functionalized and no-functionalized nanoparticles 
probably due to the low degree of conjugation. Then, we increased the 
amount of peptide testing NCs of Hep/PLL (R=1,5), pep/Hep (R=1,2). In 
this case to avoid the NCs destabilization (ζ –potential near to zero) it was 
necessary to complete the NCs saturation with PLL, adding the amount of 
polymer able to switch the charge to positive (30) (RPLL/Hep=2,2, 
Rpep/Hep=1,2). 
In other words, we prepared positively charged nanocapsules whose 
saturation of the last positively charged layer of poly-L-lysine was 
completed with gH625(6K). In particular the heparin bilayer nanocapsules 
were covered by a layer of poly-L-lysine at a concentration (RPLL/Hep=2,2) 
that doesn’t completely cover the last layer of heparin; then the saturation 
was completed by gH625(6K) (Rpep/Hep =1,2). As control saturated trilayer 
nanocapsules (PLL/Hep/PLL) were realized (Fig. 5.8). In Fig. 5.9 a 
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schematic representation of the preparation of the just mentioned 
nanocapsules is shown.  
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Figure 5.8 Size (A) and ζ –potential (B) data of the trilayer PLL/Hep/PLL  
(Size:152,0 nm, PDI:0,091,  ζ –potential: -48,2 mV) (black )and the  trilayer 
with gH625(6K)(Size: 150,2 nm, PDI: 0,109, ζ –potential:43,2 mV) (red). 
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Figure 5.9 Schematic representation of preparation of the functionalized 
trilayer nanocapsules. 1) The O/W nanoemulsion solution was added one 
shot to a solution of poly-L-lysine under stirring obtaining poly-L-lysine 
monolayer nanocapsules. 2) The poly-L-lysine monolayer nanocapsules 
solution was added one shot to a solution of heparine under stirring 
obtaining heparin/poly-L-lysine bilayer nanocapsules. 3) The heparin/poly-
L-lysine bilayer nanocapsules solution was added one shot to a solution of 
poly-L-lysine (at a lower concentration of saturation) under stirring 
obtaining unsaturated poly-L-lysine/heparin/poly-L-lysine nanocapsules. 4) 
The poly-L-lysine/heparin/poly-L-lysine bilayer nanocapsules solution was 
added to a solution of the peptide obtaining functionalized nanoparticles. 
 
Also in this case in vitro studies did not show difference between NCs with 
and without the peptide. Probably the high interaction of PLL with cells 
membrane did not allow to appreciate the difference of uptake, further it 
was not possible to test NCs with a higher degree of functionalization due to 
a destabilization in the culture medium. 
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Therefore, we moved to the same peptide with a negatively charged tail of 
six residues of glutamic acid (gH625(6E)). In Fig. 5.10 is shown the UV 
spectrum followed at 220 nm of the Analytical RP-HPLC of the purified 
peptide. 
 
Figure 5.10 UV profile (220 nm) of the RP-HPLC of the pure peptide 
gH625(6E). 
 
In this case the peptide was bound to PLL NCs (Pep/PLL=0,85) and the 
saturation was completed with HA (HA/PLL=2,5). In Fig. 5.11 data of size 
and ζ -potential of the just mentioned nanoparticles are represented. 
Experiments of uptake will be carried out to assess a difference in uptake 
between control and HA/PLL NCs bound to gH625 peptide by the proposed 
electrostatic strategy. 
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Figure 5.11 Size (A) and ζ –potential (B) data of the bilayer HA/PLL 
(Size:149,2 nm, PDI:0,076,  ζ –potential: -41,4 mV)(black) and the bilayer 
saturated with gH625(6E)(Size: 150,4 nm, PDI: 0,060, ζ –potential:-34,9 
mV)(red). 
 
 
 
5.3 Conclusions 
 
An easy strategy of attachment, based on electrostatic interaction, was 
developed in order to decorate with gH625 O/W NEs coated with a 
polymeric multilayer. The peptide was synthetized in a novel way with a tail 
of six charged amino acids in order to give it the capability to attach charged 
nanocapsules only by the tail and exploit the principle of deposition based 
on the layer by layer methodology. In this way it was possible to carry out 
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an easy and fast strategy of bio-conjugation of charged polymeric 
nanocapsules by means of a peptide projected with electrostatic properties. 
We first started with a positively charged peptide however final positive 
charged nanocapsules did not show a significant difference in uptake as 
compared with the control system whereas, low concentrations of peptides 
to keep a final negative charge was too low for a consistent and functional 
decoration. We have therefore moved to negative peptides with the aim to 
work with a final negatively charged nanocapsules and new experiments are 
under investigation. 
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Concluding Remarks and Applications  
 
 
Nanocapsules are colloidal drug carrier systems composed of an oily or an 
aqueous core surrounded by a thin polymer membrane. In particular 
biodegradable, oil core nanocapsules represent a suitable platform for 
entrapment and delivery of lipophilic drugs to treat various diseases 
(including cancer and infections). Herein, we designed injectable PEGylated 
oil core nanocapsules with a size below 200 nm, which can reach the area 
with the increased vascular permeability, and release there the active drug 
since they are completely composed of biodegradable materials (fatty acids 
and biodegradable polymers). This type of nanoparticles could represent a 
versatile platform for the treatment of different types of solid tumors. 
Anyway, in the case of brain tumors the blood brain vessels tend to keep 
their impermeable feature. For this reason, we decorated the injectable 
PEGylated oil core nanocapsules with a cell penetrating peptide (gH625) 
which, due to its amphipathic character, is able to perturb temporarily 
phospholipidic membrane organization and cross the blood brain barrier 
(BBB) carrying its cargo with it. This type of nanocapsules can also have a 
second functionality. They can accumulate in the endothelium vessels where 
could have the possibility to release their cargo over the time and treat an 
endothelial barrier dysfunction attacking inside the cell.  
In the synthesis of oil core nanocapsules ITC was employed for the first 
time to study the optimal conditions for nano-emulsion coating. As result a 
new method, based on the knowledge of the energetics of overall 
146 
 
interactions, was developed to select the polymer coating that guarantees the 
best performance in the field of drug administration.  
ITC allowed also to develop a new methodology for the measurement of the 
number of receptors on the cells. This methodology, based on the analysis 
of the energetics of interaction with a ligand, provided complete information 
on receptor overexpression in a near-physiological conditions. These 
ﬁndings could give fundamental information for an optimal design of new 
active drugs targeting towards specific tissues and shed new insights into the 
emerging ﬁeld of nanotechnology.  
In this regards future in vitro experiments could be conducted to confirm the 
good effects that the accumulation in the endothelium vessels of 
biodegradable oil core NCs, loaded with a drug, could provide on an 
endothelial barrier dysfunction. Moreover, studies could be designed to 
identify the optimal NCs rigidity to improve their crossing through the 
endothelial barrier like the blood brain barrier in order to optimize the drug 
delivery formulation for a CNS disease. The NCs rigidity could be increased 
switching from a monolayer to a multilayer polymeric coating or a solid 
shell of silica. Finally, in view of decorating the oil core polymeric NCs 
with a targeting molecule, the ITC methodology, already developed to study 
the receptor overexpression on cells, could be used to study the energetics of 
interaction directly between NCs and cells with the aim to optimize the 
formulation itself on the basis of the results. 
 
